var title_f6_46_6880="Mild Hunter syndrome A";
var content_f6_46_6880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64748%7EPEDS%2F77624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64748%7EPEDS%2F77624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mild mucopolysaccharidosis type II (MPS II, Hunter syndrome) A",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 151px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mild Hunter syndrome (MPS II) in a 12-year-old boy (frontal view).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ed Wraith, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mild mucopolysaccharidosis type II (MPS II, Hunter syndrome) B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 123px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mild Hunter syndrome (MPS II) in a 12-year-old boy (lateral view).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ed Wraith, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6880=[""].join("\n");
var outline_f6_46_6880=null;
var title_f6_46_6881="Nicorandil: International drug information";
var content_f6_46_6881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nicorandil: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adancor (FR);",
"     </li>",
"     <li>",
"      Angicor (DK);",
"     </li>",
"     <li>",
"      Dancor (AT, CH, ES, NL, PT);",
"     </li>",
"     <li>",
"      Ikorel (AU, CH, FR, GB, NL);",
"     </li>",
"     <li>",
"      Nicorandil &rdquo;Merck&rdquo; (AT);",
"     </li>",
"     <li>",
"      Nikoril (PT);",
"     </li>",
"     <li>",
"      Sigmart (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of angina",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Initial: 10 mg twice daily; dose may be titrated to 30 mg twice daily; may use 5 mg twice daily in patients prone to headache",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 10 mg, 20 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10420 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6881=[""].join("\n");
var outline_f6_46_6881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304189\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979658\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979681\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979657\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821129\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979660\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10420\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10420|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_46_6882="PMLE face";
var content_f6_46_6882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polymorphous light eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 12-year-old girl developed a pruritic eruption that consisted of discrete and coalescing erythematous papules on the face. The lesions were photodistributed and appeared within hours after intense sun exposure in the spring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6882=[""].join("\n");
var outline_f6_46_6882=null;
var title_f6_46_6883="Patient information: Shortness of breath (dyspnea) (The Basics)";
var content_f6_46_6883=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/30/33250\">",
"         Patient information: Anaphylaxis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/11/4275\">",
"         Patient information: Asthma in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/59/5043\">",
"         Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1075\">",
"         Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/13/21714\">",
"         Patient information: Dilated cardiomyopathy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/28/35266\">",
"         Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/57/15250\">",
"         Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/13/1236\">",
"         Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/17/44305\">",
"         Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/49/18197\">",
"         Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/38/30308\">",
"         Patient information: Pneumonia in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/50/28450\">",
"         Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Shortness of breath (dyspnea) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/shortness-of-breath-dyspnea-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H31616661\">",
"      <span class=\"h1\">",
"       What is shortness of breath?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who have shortness of breath describe it in different ways. Some people say that they feel like they can&rsquo;t take a deep breath in or get enough air. Other people might feel like their chest is tight or they have to work harder than usual to breathe. The medical word for shortness of breath is &ldquo;dyspnea.&rdquo;",
"     </p>",
"     <p>",
"      Shortness of breath can start suddenly, over minutes to hours. It can also happen over a longer period of time, from weeks to months.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31616668\">",
"      <span class=\"h1\">",
"       What causes shortness of breath?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different medical conditions can cause shortness of breath.",
"     </p>",
"     <p>",
"      The most common causes of shortness of breath that starts suddenly are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Lung problems, such as asthma, infections, or blood clots &mdash; These conditions might cause other symptoms, too. For example, a lung infection usually causes a fever and cough.",
"       </li>",
"       <li>",
"        Heart problems, such as a heart attack or heart failure &mdash; A heart attack can also cause chest pain or pressure. Heart failure is when the heart does not pump as well as it should.",
"       </li>",
"       <li>",
"        A severe allergic reaction, called &ldquo;anaphylaxis&rdquo; &mdash; This can also cause itching, swelling, or a rash.",
"       </li>",
"       <li>",
"        Pregnancy &mdash; It can be normal for pregnant women to feel slightly short of breath just after they lie down or are active.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The most common causes of shortness of breath that happens over weeks to months are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Lung problems, such as asthma or chronic obstructive pulmonary disease (COPD) &mdash; Both of these conditions can make it hard to breathe. COPD is usually caused by smoking.",
"       </li>",
"       <li>",
"        Heart problems, such as heart failure or a change in the size and shape of the heart (called cardiomyopathy)",
"       </li>",
"       <li>",
"        Being overweight or out of shape",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31616675\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have shortness of breath, you should see your doctor or nurse. If you have severe shortness of breath with chest pain or nausea, you need to go to the hospital. Having those symptoms could mean that your condition is serious.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31616682\">",
"      <span class=\"h1\">",
"       Will I have tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might. Your doctor or nurse will talk with you, ask about your symptoms, and do an exam. Depending on what the doctor or nurse finds, he or she might order 1 or more of the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A chest X-ray",
"       </li>",
"       <li>",
"        An electrocardiogram (ECG or EKG) to measure the electrical activity in your heart",
"       </li>",
"       <li>",
"        A breathing test",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31616689\">",
"      <span class=\"h1\">",
"       How is shortness of breath treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Shortness of breath is treated in different ways, depending on the cause. Once your doctor or nurse figures out the cause of your symptoms, he or she will talk with you about different possible treatments.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31616696\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=see_link\">",
"       Patient information: Asthma in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=see_link\">",
"       Patient information: Anaphylaxis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"       Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/13/21714?source=see_link\">",
"       Patient information: Dilated cardiomyopathy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=see_link\">",
"       Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"       Patient information: Pneumonia in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"       Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=see_link\">",
"       Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"       Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/46/6883?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16192 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-109.224.62.197-C12E3FDE9F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6883=[""].join("\n");
var outline_f6_46_6883=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31616661\">",
"      What is shortness of breath?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31616668\">",
"      What causes shortness of breath?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31616675\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31616682\">",
"      Will I have tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31616689\">",
"      How is shortness of breath treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31616696\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=related_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/13/21714?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_46_6884="Anatomy carotid sinus";
var content_f6_46_6884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the carotid sinus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter J Zimetbaum, MD and Daniel Frisch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6884=[""].join("\n");
var outline_f6_46_6884=null;
var title_f6_46_6885="Vaginectomy";
var content_f6_46_6885=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vaginectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6885/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6885/contributors\">",
"     C William Helm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6885/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6885/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6885/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6885/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/46/6885/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial and total vaginectomy refer to procedures in which the vaginal epithelium is removed without disruption of the adjacent tissues of the paracolpium. The most common indication for these procedures is treatment of vaginal intraepithelial neoplasia. Rarely, chronic benign conditions such as lichen planus may be severe enough to warrant vaginectomy. Partial vaginectomy may also be utilized to biopsy large vaginal lesions of unknown etiology. Radical vaginectomy is performed for pelvic malignancy involving or encroaching upon the vagina. It is rarely indicated. More commonly, at the time of radical hysterectomy for early cervix cancer or endometrial cancer involving the cervix, the upper third (2 to 3 cm) of the vagina is removed with some adjacent paracolpium.",
"   </p>",
"   <p>",
"    Vaginectomy is reviewed here. Conditions for which vaginectomy is indicated are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link\">",
"     \"Vaginal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=see_link\">",
"     \"Vaginal intraepithelial neoplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link\">",
"     \"Vulvar lichen planus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PARTIAL OR TOTAL VAGINECTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preoperative preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure should be clearly explained to the patient and her partner, particularly with regard to complications. The issue of vaginal reconstruction should also be raised, depending upon the amount of vagina to be removed. Thorough bowel preparation is mandatory for more extensive vaginal surgery in case of injury to the rectum or anus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link&amp;anchor=H8420779#H8420779\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\", section on 'Bowel preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Operative procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;General, epidural, or spinal anesthesia is administered. The patient may be placed in lithotomy position if the only approach is via the perineum and vaginal reconstruction is not planned. For all other procedures, the patient is placed in a modified frog leg position in Allen stirrups.",
"   </p>",
"   <p>",
"    A total abdominal or vaginal hysterectomy is usually performed concurrently in women with an intact uterus who require total vaginectomy or upper partial vaginectomy. If two surgeons are available, a combined abdominoperineal approach facilitates the surgery. For women who have previously undergone hysterectomy, it is possible to perform total vaginectomy entirely from below. Great care must be taken to include all vaginal skin in the angles and vault of the vagina.",
"   </p>",
"   <p>",
"    Whether a total or partial vaginectomy is to be performed the vagina is initially inspected and the margins of resection identified. Placing one or more sutures to mark the extent of planned resection or staining the vagina may facilitate subsequent dissection, particularly if the procedure is being performed by the abdominal route. If a lesion is to be excised, then the placement of sutures at key points around it is particularly useful. When small lesions are excised, the mucosa of the vagina can be closed using",
"    <span class=\"nowrap\">",
"     3/0",
"    </span>",
"    polyglactin sutures.",
"   </p>",
"   <p>",
"    In a combined abdomino-vaginal procedure, the vaginal part of the procedure is usually quicker than the abdominal so the vaginal operator may delay this dissection until the uterus has been mobilized. The lower incision is made with a scalpel circumferentially cutting around the vagina. Forceps are applied to the upper edge; applying gentle traction allows the operator to dissect the vaginal skin off underlying structures with scissors. Care must be taken anteriorly over the urethra because the tough underlying connective tissue makes dissection difficult. \"Buttonholes\" and tears of the vagina should be avoided. Dissection is continued as far up the vagina as can be reached easily. Bleeding from venous sinuses often requires running sutures. Bleeding may be reduced by the prophylactic injection of a vasoconstricting agent such as epinephrine diluted to 1 to 100,000 in saline.",
"   </p>",
"   <p>",
"    The abdominal surgeon performs the first stages of a total abdominal hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32490?source=see_link\">",
"     \"Abdominal hysterectomy\"",
"    </a>",
"    .) Broad ligaments are taken, uterine arteries are divided and ligated in the normal fashion, the uterovesical fold of peritoneum is also divided, and the bladder dissected off the vagina. The bladder dissection is aided by traction on Kelly forceps applied to the peritoneal edge over the bladder and simultaneous traction on the uterus, which stretches the vagina (",
"    <a class=\"graphic graphic_figure graphicRef54784 \" href=\"UTD.htm?10/22/10594\">",
"     figure 1",
"    </a>",
"    ). Sharp dissection should be used to reduce bleeding and preserve tissue planes. The dissection should be continued laterally underneath the path of the distal ureters on each side. The peritoneum in the posterior cul-de-sac (pouch of Douglas) is incised close to its attachment to the cervix and vagina, and the rectum is dissected gently away. This dissection can be completed readily with the assistance of the perineal surgeon.",
"   </p>",
"   <p>",
"    Straight Zeppelin forceps are placed on the paravaginal tissues along the line of the vagina medial to the uterine artery pedicles. A scalpel is used to divide the tissues on the vaginal side and the pedicle is transfixed and ligated. It is important to ensure that the ureters are not caught in the forceps or resulting pedicle. If the ureters cannot be clearly identified, they should be dissected off the parametrium after deroofing the ureteric tunnel employing a technique similar to that used for radical hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14730?source=see_link\">",
"     \"Radical hysterectomy\"",
"    </a>",
"    .) Additional pedicles are taken until the lower limit of resection is reached. At a convenient moment, the vagina is opened anteriorly from above, with the perineal surgeon guiding the point of entry.",
"   </p>",
"   <p>",
"    Following removal of the specimen, hemostasis is secured using electrocauterization and suture ligatures. The procedure now depends upon the extent of the vaginectomy and the need for vaginal reconstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Previous hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient has had a previous hysterectomy, total or partial vaginectomy can be performed separately, from above or below. There are proponents of both routes, but the abdominal approach has the advantage of allowing better visualization and dissection of the ureters, and a more complete excision of the vault and the corners of the vaginal vault where intraepithelial neoplasia can be hidden. Bowel adherent to the vault can also be dissected free.",
"   </p>",
"   <p>",
"    In the abdominal approach, the vault of the vagina is identified with the aid of a gauze roll on a sponge-holder placed in the vagina to stretch up the vault. The peritoneum over the vault is incised and the bladder is dissected off the vagina with dissecting scissors. The posterior cul-de-sac peritoneum is incised and the rectum is separated from the vagina and uterosacral ligaments. The course of the ureters may have been distorted as a result of previous surgery. Therefore, care must be taken to identify them, and they may require dissecting out to clear the area of the upper vagina, as with a radical hysterectomy. Once the bladder, ureters, and rectum are clear, the dissection continues as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;If no vaginal reconstruction is to be performed, the vaginal defect can be allowed to close off. A suction drain may be brought out through the abdomen or perineum. If there is persistent oozing, a povidone-iodine-soaked pack can be inserted for 24 to 48 hours with its tail brought out through the perineum.",
"   </p>",
"   <p>",
"    If an upper vaginectomy has been undertaken and vaginal reconstruction is not planned, the edges of the residual vagina may be run from above with continuous 0 polyglactin suture for hemostasis and left open, or closed with interrupted sutures. If there is only residual vaginal skin at the lower end, no special closure is necessary, although it is sometimes possible to mobilize the residual skin and sew the anterior and posterior edges together to prevent sequestration of vaginal epithelium in which intraepithelial neoplasia may develop.",
"   </p>",
"   <p>",
"    Following the extensive dissection close to bladder and ureters, competence of the ureters and bladder can be tested by injecting 5 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    intravenously before closure; the dye will turn the urine blue. With the catheter temporarily occluded, the bladder will distend, thus making it easier to examine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RADICAL VAGINECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal difference between radical and nonradical vaginectomy is the extent of resection of tissues lateral to the upper half of the vagina. Total radical vaginectomy is usually performed together with removal of either the bladder or rectum, or both as part of a pelvic exenteration for pelvic malignancy. In gynecologic oncology, radical vaginectomy is most commonly performed to treat carcinoma of the cervix that has recurred in the cervix and upper vagina following first-line therapy with chemo-radiation. Partial radical upper vaginectomy may be performed routinely as part of a radical hysterectomy for early carcinoma of the cervix. Also, if an occult early cervical cancer is discovered incidentally following a simple hysterectomy, partial radical upper vaginectomy may be performed with radical parametrectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Operative procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;When performed concurrently with radical hysterectomy or parametrectomy, but not as part of an exenteration procedure, the distal ureters and bladder are dissected from the upper vagina, paracolpium, and parametrium. The rectum is separated from the vagina and uterosacral ligaments and the uterosacral ligaments are divided as part of the radical hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14730?source=see_link\">",
"     \"Radical hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A nerve-sparing technique to preserve the autonomic nerves to the bladder should be used whenever possible at the time of upper vaginectomy performed with radical hysterectomy. &nbsp;",
"   </p>",
"   <p>",
"    The parametrial tissues are clamped and ligated. Following this, the bladder and ureters are gently elevated by retractors and, while the uterus and vagina are stretched cephalad, the surgeon dissects the bladder distally off the vagina. The excisional part of the procedure is completed when the vagina is transected at the required level. If the whole vagina is to be removed, it is best for two surgeons to work together. As the abdominal surgeon dissects the ureters, bladder and rectum away from the vagina, parametrium and paracolpium, the perineal surgeon pushes the vagina medially and guides placement of the Zeppelin forceps onto these tissues by the abdominal surgeon (",
"    <a class=\"graphic graphic_figure graphicRef82261 \" href=\"UTD.htm?21/61/22482\">",
"     figure 2",
"    </a>",
"    ). The upper lateral tissues of the paracolpium are clamped, divided, and ligated until the vagina is freed on both sides. Hemostasis is then secured and vaginal reconstruction is performed, if planned.",
"   </p>",
"   <p>",
"    A laparoscopic approach can be used for upper radical vaginectomy performed both at the time of radical hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6885/abstract/1\">",
"     1",
"    </a>",
"    ] and at the time of total pelvic exenteration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6885/abstract/2\">",
"     2",
"    </a>",
"    ]. Although it is necessary to remove the upper 2 to 3 cm of the vagina at the time of radical hysterectomy for cervix cancer, preservation of bladder function can be facilitated by avoidance of injury to the autonomic nerves running in the dorsal and posterior part of the parametrium. Care should be taken to restrict resection to only the medial paracolpium tissues in the upper third of the vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6885/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Postoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the bladder has been left in situ, a 16 French Foley catheter is inserted suprapubically at the time of surgery. This allows bladder function to be assessed postoperatively before catheter removal. If a perineal pack has been placed, it is removed after 24 to 48 hours. The patient is encouraged to resume a normal diet postoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major postoperative complications are urinary and rectal fistula and chronic bladder and rectal dysfunction. These problems are more common after radical vaginectomy than total or partial procedures. Bladder dysfunction is markedly reduced using a nerve-sparing technique when upper vaginectomy is performed at the time of radical hysterectomy. Radical vaginal surgery may also alter body image perception and cause severe psychosexual problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     VAGINAL RECONSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of vaginal reconstruction are to promote rapid wound healing, decrease pelvic dead space, restore the pelvic floor, and reestablish good sexual function and body image [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6885/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaginal reconstruction may be indicated in women who have vaginal defects from treatment of benign disease, gynecological cancer, or nongynecological cancer invading or in close proximity to the vagina.",
"   </p>",
"   <p>",
"    Vaginal reconstruction is best performed at primary surgery because the cavity is \"ready\" and does not require further dissection. Delayed procedures are more difficult because of scarring and soft tissue contracture. In older women with severe utero-vaginal prolapse the vagina may be resected and the cavity obliterated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6885/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If only vaginectomy has been performed, without removal of the bladder or rectum, a number of techniques are available. A split-thickness skin graft may be applied to the residual tissues, if sufficient, or to an omental tube. A full-thickness skin graft, a transposition skin flap (eg, pudendal thigh flap [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6885/abstract/6\">",
"     6",
"    </a>",
"    ]), or a sigmoid colon or cecal neovagina are alternatives. Myocutaneous flaps are too bulky after nonradical surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=see_link&amp;anchor=H23#H23\">",
"     \"Diagnosis and management of congenital anomalies of the vagina\", section on 'Vaginal agenesis'",
"    </a>",
"    .) The use of an acellular dermal graft has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6885/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following vaginectomy in combination with exenteration, reconstruction of a neovagina with skin flaps is inadequate due to poor vascularity, dead space, and lack of pelvic support. Myocutaneous flaps bring bulky vascularized tissue into the pelvis, which reduces the chance of the empty pelvis syndrome developing. Possibilities include gracilis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6885/abstract/8\">",
"     8",
"    </a>",
"    ] and rectus abdominis flaps [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6885/abstract/9\">",
"     9",
"    </a>",
"    ], with the latter being more reliable [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6885/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early complications include infection, delayed wound healing, loss of the flap due to necrosis, fistula formation, and small bowel herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6885/abstract/4\">",
"     4",
"    </a>",
"    ]. After the reconstructed vagina has healed, sexual function may be painful or otherwise unsatisfactory due a vagina that is too short, too narrow or wide, too dry or wet, or insensitive. Pre- and post-operative psychosexual counseling may help patients with these issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial and total vaginectomy refer to procedures in which the vaginal epithelium is removed without disruption of tissues of the paracolpium. The most common indication for partial vaginectomy is vaginal intraepithelial neoplasia. Radical vaginectomy refers to resection with part or all of the paravaginal tissues (paracolpium). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Partial or total vaginectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Total abdominal or vaginal hysterectomy may be performed concurrently in women with an intact uterus who require total vaginectomy or upper partial vaginectomy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Operative procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal or laparoscopic approaches (as opposed to vaginal) provide better visualization for dissection of the ureters, and a more complete excision of the vaginal vault and, particularly, the corners of the vaginal vault where intraepithelial neoplasia can be sequestered. Bowel adherent to the vault can also be dissected free more safely. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Operative procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If no vaginal reconstruction is to be performed, the vaginal defect can be allowed to close off. If vaginal reconstruction is desired, it can be performed at the time of vaginectomy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major postoperative complications are urinary and rectal fistula and chronic bladder and rectal dysfunction. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A nerve-sparing technique to preserve the autonomic nerves to the bladder should be used whenever possible at the time of upper vaginectomy performed with radical hysterectomy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Radical vaginectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6885/abstract/1\">",
"      Kavallaris A, Hornemann A, Chalvatzas N, et al. Laparoscopic nerve-sparing radical hysterectomy: description of the technique and patients' outcome. Gynecol Oncol 2010; 119:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6885/abstract/2\">",
"      Pomel C, Rouzier R, Pocard M, et al. Laparoscopic total pelvic exenteration for cervical cancer relapse. Gynecol Oncol 2003; 91:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6885/abstract/3\">",
"      Rob L, Halaska M, Robova H. Nerve-sparing and individually tailored surgery for cervical cancer. Lancet Oncol 2010; 11:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6885/abstract/4\">",
"      Pusic AL, Mehrara BJ. Vaginal reconstruction: an algorithm approach to defect classification and flap reconstruction. J Surg Oncol 2006; 94:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6885/abstract/5\">",
"      Hoffman MS, Cardosi RJ, Lockhart J, et al. Vaginectomy with pelvic herniorrhaphy for prolapse. Am J Obstet Gynecol 2003; 189:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6885/abstract/6\">",
"      Wee JT, Joseph VT. A new technique of vaginal reconstruction using neurovascular pudendal-thigh flaps: a preliminary report. Plast Reconstr Surg 1989; 83:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6885/abstract/7\">",
"      Stany MP, Winter WE 3rd, Elkas JC, Rose GS. The use of acellular dermal graft for vulvovaginal reconstruction in a patient with lichen planus. Obstet Gynecol 2005; 105:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6885/abstract/8\">",
"      Copeland LJ, Hancock KC, Gershenson DM, et al. Gracilis myocutaneous vaginal reconstruction concurrent with total pelvic exenteration. Am J Obstet Gynecol 1989; 160:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6885/abstract/9\">",
"      Tobin GR, Pursell SH, Day TG Jr. Refinements in vaginal reconstruction using rectus abdominis flaps. Clin Plast Surg 1990; 17:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6885/abstract/10\">",
"      Soper JT, Secord AA, Havrilesky LJ, et al. Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity. Int J Gynecol Cancer 2007; 17:298.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3281 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-124.240.187.80-5DB13EDD60-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6885=[""].join("\n");
var outline_f6_46_6885=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PARTIAL OR TOTAL VAGINECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preoperative preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Operative procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Previous hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RADICAL VAGINECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Operative procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Postoperative management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      VAGINAL RECONSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3281\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3281|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/22/10594\" title=\"figure 1\">",
"      Exposing the upper vagina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/61/22482\" title=\"figure 2\">",
"      Radical vaginectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32490?source=related_link\">",
"      Abdominal hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=related_link\">",
"      Diagnosis and management of congenital anomalies of the vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14730?source=related_link\">",
"      Radical hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=related_link\">",
"      Vaginal intraepithelial neoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=related_link\">",
"      Vulvar lichen planus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_46_6886="Insulin NPH and insulin regular: Pediatric drug information";
var content_f6_46_6886=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin NPH and insulin regular: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/26/18855?source=see_link\">",
"    see \"Insulin NPH and insulin regular: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6341?source=see_link\">",
"    see \"Insulin NPH and insulin regular: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2137923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumuLIN&reg; 70/30;",
"     </li>",
"     <li>",
"      NovoLIN&reg; 70/30",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2186441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humulin&reg; 20/80;",
"     </li>",
"     <li>",
"      Humulin&reg; 70/30;",
"     </li>",
"     <li>",
"      Novolin&reg; ge 30/70;",
"     </li>",
"     <li>",
"      Novolin&reg; ge 40/60;",
"     </li>",
"     <li>",
"      Novolin&reg; ge 50/50",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2984451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Insulin, Combination",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2984459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/26/18855?source=see_link\">",
"      see \"Insulin NPH and insulin regular: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin NPH is an intermediate-acting insulin and regular insulin is a short-acting insulin administered by SubQ injection. When compared to insulin NPH, the combination product (insulin NPH and insulin regular) has a shorter onset of action and a similar duration of action. With combination insulin products, the proportion of short-acting to long-acting insulin is fixed in the combination products; basal vs prandial dose adjustments cannot be made. Fixed ratio insulins (such as insulin NPH and insulin regular combination) are typically administered as 2 daily doses with each dose intended to cover two meals and a snack. Because of variability in the peak effect and individual patient variability in activities, meals, etc, it may be more difficult to achieve complete glycemic control using fixed combinations of insulins; frequent monitoring and close medical supervision may be necessary. See Insulin Regular for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 1 diabetes mellitus:",
"     </b>",
"     Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined",
"     </b>",
"     . Insulin NPH and insulin regular combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     SubQ: 0.5-1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): Adults: SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Insulin NPH and insulin regular combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing. Dosage must be carefully adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Insulin requirements are reduced due to changes in insulin clearance or metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumuLIN&reg; 70/30: Insulin NPH suspension 70% [intermediate acting] and insulin regular solution 30% [short acting]: 100 units/mL (3 mL) [prefilled pen, vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumuLIN&reg; 70/30: Insulin NPH suspension 70% [intermediate acting] and insulin regular solution 30% [short acting]: 100 units/mL (10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     NovoLIN&reg; 70/30: Insulin NPH suspension 70% [intermediate acting] and insulin regular solution 30% [short acting]: 100 units/mL  (10 mL) [vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2344735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2984460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: SubQ: Gently roll vial or pen in the palms of the hands to resuspend before use; administer into the subcutaneous fat of the thighs, arms, buttocks, or abdomen, with sites rotated. Cold injections should be avoided. Administer within 15 minutes before a meal (before breakfast and supper).  Do not mix or dilute with other insulins.",
"     <b>",
"      Not for I.V. administration",
"     </b>",
"     or use in an insulin infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2137936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     A universal sterile diluent, Sterile Diluent for Humalog&reg;, Humulin&reg; N, Humulin&reg; R, Humulin&reg; 70/30, and Humulin&reg; R U-500, is available from the manufacturer for SubQ administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Insulin aspart, insulin detemir, insulin glargine, insulin glulisine, insulin lispro.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2984456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix or dilute with other insulins.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Humulin&reg; 70/30 vials: Store unopened vials in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; keep away from heat and sunlight. Once punctured (in use), vials may be stored for up to 31 days in the refrigerator between 2&deg;C and 8&deg;C (36&deg;F to 46&deg;F) or at room temperature &le;30&deg;C (&le;86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Humulin&reg; 70/30 pens: Store unopened pen in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; keep away from heat and sunlight. Once punctured (in use), pen should be stored at room temperature 15&deg;C  to 30&deg;C (59&deg;F to 86&deg;F) for up to 10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Novolin&reg; 70/30 vials: Store unopened vials in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) until product expiration date or at room temperature &le;25&deg;C (&le;77&deg;F) for up to 42 days; do not freeze; keep away from heat and sunlight. Once punctured (in use), store vials at room temperature &le;25&deg;C (&le;77&deg;F) for up to 42 days (this includes any days stored at room temperature prior to opening vial); refrigeration of in use vials is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2984452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM); type 2 diabetes mellitus (noninsulin dependent, NIDDM) to control hyperglycemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2137921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HumuLIN&reg; 70/30 may be confused with HumaLOG&reg; Mix 75/25, HumuLIN&reg; R, NovoLIN&reg; 70/30, NovoLOG&reg; Mix 70/30",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NovoLIN&reg; 70/30 may be confused with HumaLOG&reg; Mix 75/25, HumuLIN&reg; 70/30, HumuLIN&reg; R, NovoLIN&reg; R, and NovoLOG&reg; Mix 70/30",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8102908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2984454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to regular insulin, NPH insulin, or any component; hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2984462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and adjust dosage in patients with renal impairment; use with caution and monitor closely in patient with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2984455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypoglycemia is the most common adverse effect of insulin. The timing of hypoglycemia differs among various insulin formulations. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage. Hypoglycemia may result from increased work or exercise without eating. Not for I.V. infusion or use in insulin infusion pumps.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8102910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2984465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution with chromium, garlic, gymnema (may increase hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2137927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2984467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urine sugar and acetone, serum glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , lipid profile",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2984468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 30-90 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 70-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control with type 1 diabetes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;6 years: &le;8.5% and &ge;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: &lt;8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     13-19 years: &lt;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma glucose*:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preprandial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 90-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13 years to Adults: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bedtime and overnight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 110-200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13-19 years: 90-150 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak postprandial** : Adults: &lt;180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     *Plasma glucose concentrations are generally 10% to 15% higher than those in whole blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     **Peak postprandial plasma glucose is measured 1-2 hours after a meal",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2984457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Insulin facilitates entry of glucose into muscle, adipose, and other tissues via hexose transporters, including GLUT4. Insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Target organs for insulin include the liver, skeletal muscle, and adipose tissue. Within the liver, insulin stimulates hepatic glycogen synthesis through the activation of the enzymes hexokinase, phosphofructokinase, and glycogen synthase as well as the inhibition of glucose-6 phosphatase. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes. Insulin also directly inhibits the hydrolysis of triglycerides.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on promptness and duration of effect, including rapid-, short-, intermediate-, and long-acting insulins. Insulin NPH and insulin regular is a combination insulin product with intermediate-acting characteristics.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2984466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Novolin&reg; 70/30, Humulin&reg; 70/30: 0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Novolin&reg; 70/30, Humulin&reg; 70/30: 1.5-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Novolin&reg; 70/30, Humulin&reg; 70/30: Up to 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2984458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2984469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6341?source=see_link\">",
"      see \"Insulin NPH and insulin regular: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by healthcare provider. This medication is used to control diabetes; it is not a cure. It is imperative to follow other components of prescribed treatment (eg, diet and exercise regimen). Take exactly as directed. Do not change dose or discontinue unless advised by healthcare provider. If you experience hypoglycemic reaction, contact healthcare provider immediately. Always carry quick source of sugar with you. Monitor glucose levels as directed by healthcare provider. Report adverse side effects, including chest pain or palpitations; persistent fatigue, confusion, headache; skin rash or redness; numbness of mouth, lips, or tongue; muscle weakness or tremors; vision changes; respiratory difficulty; or nausea, vomiting, or flu-like symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14455400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the daily insulin dose is given as an intermediate-acting or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate-acting or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin formulations 3 or more times daily.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12846 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6886=[""].join("\n");
var outline_f6_46_6886=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137923\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2186441\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984451\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984459\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104228\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2344735\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984460\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137936\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984456\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984452\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137921\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102908\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984454\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984462\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984455\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102910\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221043\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984465\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137927\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984467\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984468\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984457\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984466\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984458\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984469\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455400\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12846\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12846|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/26/18855?source=related_link\">",
"      Insulin NPH and insulin regular: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6341?source=related_link\">",
"      Insulin NPH and insulin regular: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_46_6887="Presentation and diagnosis of rotator cuff tears";
var content_f6_46_6887=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Presentation and diagnosis of rotator cuff tears",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6887/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6887/contributors\">",
"     Stephen M Simons, MD, FACSM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6887/contributors\">",
"     J Bryan Dixon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6887/contributors\">",
"     David Kruse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6887/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6887/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6887/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6887/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/46/6887/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder pain is a common presenting complaint to primary care offices and sports medicine clinics. Estimates of the prevalence of shoulder pain range from 16 to 34 percent in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Rotator cuff pathology is the most common condition of the shoulder for which patients seek treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/3\">",
"     3",
"    </a>",
"    ]. Estimates published in 2004 by the United States (US) Agency for Health Care Research and Quality and US Department of Health and Human Services show rotator cuff problems accounted for more than 4.5 million clinician visits and approximately 40,000 surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this burden on patients and health care resources, there remains significant controversy regarding the etiology of rotator cuff injuries, the role of rotator cuff tears in generating shoulder pain, and the ability of commonly accepted clinical tests to diagnose rotor cuff tears.",
"   </p>",
"   <p>",
"    The etiology, presentation, and diagnosis of rotator cuff tears will be reviewed here. The treatment of rotator cuff tears, rotator cuff tendinopathy, the shoulder examination, and the general management of patients with shoulder pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25095?source=see_link\">",
"     \"Management of rotator cuff tears\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27834?source=see_link\">",
"     \"Physical examination of the shoulder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND BIOMECHANICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomy and biomechanics of the shoulder generally are discussed in detail separately (",
"    <a class=\"graphic graphic_figure graphicRef72709 graphicRef54102 graphicRef69995 \" href=\"UTD.htm?35/8/35978\">",
"     figure 1A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the patient with shoulder complaints\", section on 'Anatomy and biomechanics'",
"    </a>",
"    .) The biomechanics of the rotator cuff specifically are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link&amp;anchor=H5#H5\">",
"     \"Rotator cuff tendinopathy\", section on 'Relevant anatomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link&amp;anchor=H6#H6\">",
"     \"Rotator cuff tendinopathy\", section on 'Basic biomechanics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of underlying rotator cuff tendinopathy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cause of rotator cuff tears is likely multifactorial. Degeneration, impingement, and overload may all contribute in varying degrees to the development of rotator cuff tears.",
"   </p>",
"   <p>",
"    Several theories have developed to explain the cause of rotator cuff injury. In 1934, Codman theorized that rotator cuff tears developed from intrinsic tissue degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/3\">",
"     3",
"    </a>",
"    ]. This theory was bolstered by Rothman and Parke, who suggested in 1965 that a \"critical zone\" of hypovascularity in the rotator cuff predisposed the tendon to degeneration. The role of intrinsic factors was challenged in 1972 by Neer, who suggested that impingement from extrinsic structures caused rotator cuff tears [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent investigations in throwing athletes suggest that tension overload contributes to these injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Tension overload is thought to occur when the ability of the rotator cuff to compress and maintain the stability of the glenohumeral joint is overwhelmed by the distractive forces of throwing or trama. In other words, rotator cuff muscle weakness allows subluxation of the glenohumeral joint, leading to impingement, which contributes to the development of rotator cuff tears.",
"   </p>",
"   <p>",
"    Most often rotator cuff lesions appear to start as partial tears of the undersurface or articular portion of the supraspinatus tendon [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/4\">",
"     4",
"    </a>",
"    ]. Over time they can progress to full thickness tears to include the supraspinatus, infraspinatus, subscapularis and biceps tendons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain and weakness may be the presenting complaints of the patient with rotator cuff tear. Classically, rotator cuff tears are associated with pain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Pain is said to develop over the lateral deltoid and is exacerbated by overhead activities and at night (possibly when the patients lies on the shoulder).",
"   </p>",
"   <p>",
"    This classic description may be inaccurate. Several observational studies suggest that pain associated with rotator cuff tears, when present, is nonspecific and may be due to associated subacromial bursitis, not the tear itself [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Other observational studies suggest a large portion of rotator cuff tears are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Although some degeneration of the rotator cuff may be inevitable in most individuals beyond the fifth decade of life, these degenerative changes do not necessarily cause significant functional impairment.",
"   </p>",
"   <p>",
"    To confuse matters further, some researchers find that increasing tear size correlates with more severe symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/10,14\">",
"     10,14",
"    </a>",
"    ], while others maintain that partial thickness tears create significantly more pain and disability than full thickness tears [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The understanding of the relationship between rotator cuff tears and shoulder pain is evolving. Clinicians should not allow the presence or absence of pain to play too significant a role in diagnosis.",
"   </p>",
"   <p>",
"    Weakness is another frequently cited symptom of rotator cuff tears and in large or full thickness tears represents an integral part of the diagnosis. Weakness may be apparent in otherwise asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. However, using the physical examination to isolate rotator cuff weakness can be problematic. In addition, pain from bursitis, impingement, or trauma can lead to reflex muscle inhibition and weakness unrelated to rotator cuff injury. Distinguishing between reflex muscle inhibition and true weakness is the rationale behind using a diagnostic injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    as part of the clinical evaluation for rotator cuff tears. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotator cuff tears are primarily a disease of middle aged and older patients. Observational data reveals a nearly linear increase in the frequency of rotator cuff tears over time [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/4,10,11,13,14,20-23\">",
"     4,10,11,13,14,20-23",
"    </a>",
"    ]. However, a sizeable portion of tears in older patients are asymptomatic. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Sports and occupations requiring overhead activity produce a high frequency of rotator cuff tears. In these patients, tears may present at a younger age and are frequently associated with labral pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Smoking may be a risk factor for rotator cuff tear, as may obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trauma can cause rotator cuff tears. One study found that 58 percent of patients presenting to the emergency department with acute shoulder trauma and normal radiographs who were unable to abduct above 90 degrees had acute traumatic tears of the rotator cuff [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/21\">",
"     21",
"    </a>",
"    ]. Tears were diagnosed by ultrasound during follow-up evaluations performed a median of 13 days following the injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many textbooks and clinicians have long advocated the use of physical examination to determine the presence of rotator cuff pathology, well-performed studies to support particular examination techniques or approaches are scarce. Based on the available literature and our clinical experience, we use a combination of three tests to determine the presence of rotator cuff tear and the need for further work-up:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Painful arc sign (",
"      <a class=\"graphic graphic_picture graphicRef70787 \" href=\"UTD.htm?0/11/177\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drop arm sign (failure to smoothly control shoulder adduction)",
"     </li>",
"     <li>",
"      Weakness in external rotation (",
"      <a class=\"graphic graphic_picture graphicRef77117 \" href=\"UTD.htm?28/13/28882\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Performance of these and other examination techniques for the shoulder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27834?source=see_link&amp;anchor=H1180003#H1180003\">",
"     \"Physical examination of the shoulder\", section on 'Examination for rotator cuff pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This approach is based primarily on a prospective observational study of 552 patients who were systematically evaluated using eight common shoulder examination tests and then underwent diagnostic arthroscopic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/26\">",
"     26",
"    </a>",
"    ]. Logistic regression analysis showed that a combination of a positive painful arc sign, drop arm sign, and weakness in external rotation accurately predicts full-thickness rotator cuff tear (LR 15.57; post-test probability 0.91), while a combination of three negative tests makes the diagnosis unlikely (LR 0.16; post-test probability 0.09). This study is among the few well-performed trials to assess shoulder examination techniques that include a sufficient number of patients to draw meaningful conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another prospective observational trial assessed the accuracy of 23 clinical tests in 400 patients who subsequently underwent arthroscopic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/20\">",
"     20",
"    </a>",
"    ]. In this study, patients presenting with shoulder pain that had supraspinatus weakness, weakness in external rotation, and a positive impingement sign had a 98 percent chance of full thickness tear. If the patient was 60 years of age or older, only two of these three tests needed to be positive to have a 98 percent chance of tear. The study did not include descriptions of the techniques used for clinical testing, making replication of their protocol problematic. We have included descriptions of the most commonly used tests for the signs they describe (",
"    <a class=\"graphic graphic_picture graphicRef77117 \" href=\"UTD.htm?28/13/28882\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74738 \" href=\"UTD.htm?1/60/1987\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60425 \" href=\"UTD.htm?19/27/19891\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76237 \" href=\"UTD.htm?43/7/44149\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If one assumes a pretest probability for rotator cuff tear of 30 to 70 percent, the combination of clinical tests described in either of these studies would effectively rule in full thickness tears if all were positive. If all were negative, the latter study's combination would rule out full thickness rotator cuff tear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/20\">",
"     20",
"    </a>",
"    ] while the former study's combination would rule out full thickness tear in patients over 60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of studies assessing clinical tests for the shoulder found a wide range of approaches and methodologic quality, thereby precluding meaningful metaanalysis of tests for rotator cuff integrity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, individual analyses of the 15 available studies showed that only 8 studies met quality criteria and none of the individual clinical tests included in these studies were consistently diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/27\">",
"     27",
"    </a>",
"    ]. This highlights the difficulty in recommending evidence-based clinical tests for rotator cuff tears and the importance of continued research. Accurate diagnosis of partial thickness tears or tears of specific rotator cuff muscles and tendons through clinical testing remains challenging, and our review of the literature did not yield sufficient evidence to recommend any particular test or combination of tests to diagnose these conditions.",
"   </p>",
"   <p>",
"    The concept of muscle lag provides the basis for several published tests of rotator cuff integrity, including the external rotation lag sign, internal rotation lag sign, drop sign or dropping sign, belly press test or Napoleon sign, and the belly off test [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. These tests exploit the biomechanical length-tension curve of muscle force generation and the antagonistic actions of the rotator cuff muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/28\">",
"     28",
"    </a>",
"    ]. Further study is required before we can recommend routine use of muscle lag tests to diagnose rotator cuff tear.",
"   </p>",
"   <p>",
"    To assess muscle lag, the muscle is passively placed in its maximally shortened position. When placed in this position, the ability of the muscle to exert force is minimized. The patient is then asked to maintain that position with active contraction. The difference between this passive and active range of motion is called the lag. Lag represents an inability of the muscle to resist the antagonistic force of the opposing rotator cuff muscle and is thought to identify subtle decreases in rotator cuff strength, which clinically represent tears. Loss of strength or integrity in the antagonistic muscles, decreases in passive range of motion, or neurologically mediated strength deficits can confound results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although usually normal, anterior-posterior, lateral, and outlet views of the shoulder can be of value in assessing large, chronic rotator cuff tears. These studies can help to confirm the diagnosis by showing whether the humeral head is migrating relative to the glenoid and acromion. The clinician can expect larger rotator cuff tears (&gt;1.75 cm) and probable involvement of both the supraspinatus and the infraspinatus among individuals with a symptomatic shoulder and humeral migration on plain radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/31\">",
"     31",
"    </a>",
"    ]. Plain films also allow for the evaluation of some concomitant or alternative shoulder pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Musculoskeletal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal ultrasound (MSK US) is an accurate tool for the evaluation of superficial tendon and muscle lesions, as well as bursitis, of the shoulder, and enables dynamic examination at the bedside. Its role in the evaluation of the rotator cuff is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging (MRI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI accurately diagnoses full thickness rotator cuff tears and many partial tears [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. MRI provides information about the degree of tear, tendon retraction, and muscle atrophy, all of which is critical in preoperative planning for rotator cuff repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25095?source=see_link\">",
"     \"Management of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interpretation of the MRI should be clinically correlated due to the high rate of asymptomatic tears. An observational study of MRI performed in 96 asymptomatic individuals showed rotator cuff tears in 34 percent of subjects, and nearly 54 percent of those over 60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/12\">",
"     12",
"    </a>",
"    ]. MRI can be used if the diagnosis remains unclear after initial evaluation or if definitive confirmation of the diagnosis is needed for guidance about surgery or return to sport.",
"   </p>",
"   <p>",
"    Rotator cuff tears are diagnosed on MRI based upon discontinuity of the tendon on T-1 weighted images and a fluid signal on T-2 weighted images. Ancillary findings include fluid in the subacromial space on T-2 images, loss of the subacromial fat plane on T-1 images, and proliferative spur formation of the acromion or acromioclavicular joint. Large chronic tears may be associated with cephalad migration of the humeral head and fatty atrophy of the supraspinatus and infraspinatus muscle bellies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition to rotator cuff pathology, MRI allows visualization of periarticular soft tissues, including the capsulolabral complex and biceps tendon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58593528\">",
"    <span class=\"h2\">",
"     Arthrography with MRI or CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance arthrography (MRI-A) is more sensitive and specific for diagnosing partial thickness rotator cuff tears than standard MRI, but it too has limited accuracy, especially for certain types of tears [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In addition, MRI-A is not usually obtained as part of the diagnostic workup for rotator cuff tears and is usually reserved for cases when a labral injury is suspected.",
"   </p>",
"   <p>",
"    According to small prospective studies using findings at arthroscopy as the gold standard, the diagnostic performance of arthrography with computed tomography (CT) is similar to that of MRI-A for detecting rotator cuff tears [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6887/abstract/36\">",
"     36",
"    </a>",
"    ]. CT arthrography may be useful in patients requiring more sophisticated imaging to assess the rotator cuff but who cannot undergo MRI-A (eg, body metal, pacemaker). The role of arthrography with MR or CT to assess the shoulder is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36425?source=see_link&amp;anchor=H7#H7\">",
"     \"Radiologic evaluation of the painful shoulder\", section on 'Arthrography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/53/29522?source=see_link\">",
"       \"Patient information: Rotator cuff injury (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=see_link\">",
"       \"Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rotator cuff tears are common, particularly in older adults. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of rotator cuff tears is multifactorial. Chronic tears likely represent the culmination of degeneration and impingement. Trauma can produce acute tears of the rotator cuff. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many rotator cuff tears are asymptomatic. Patients with symptoms may complain of shoulder pain, weakness, and difficulty with overhead or reaching activities. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of three clinical tests (painful arc, drop arm sign, and weakness on external rotation) can accurately diagnose full thickness rotator cuff tears in patients older than 60 years of age. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The identification of partial tears of the rotator cuff and tears of individual rotator cuff tendons remains a clinical challenge and the use of clinically correlated imaging is needed to make the diagnosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Musculoskeletal ultrasound and MRI can accurately make the diagnosis of rotator cuff tear. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/1\">",
"      Urwin M, Symmons D, Allison T, et al. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. Ann Rheum Dis 1998; 57:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/2\">",
"      Silverstein BA, Viikari-Juntura E, Fan ZJ, et al. Natural course of nontraumatic rotator cuff tendinitis and shoulder symptoms in a working population. Scand J Work Environ Health 2006; 32:99.",
"     </a>",
"    </li>",
"    <li>",
"     McFarland EG. Examination of the shoulder. In: The Complete Guide, Kim TK, Park HB, Rassi GE, et al.  (Eds), Thieme Medical Publishers, New York 2006. p.142.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/4\">",
"      Oh LS, Wolf BR, Hall MP, et al. Indications for rotator cuff repair: a systematic review. Clin Orthop Relat Res 2007; 455:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/5\">",
"      Andrews, JR, Angelo, RL. Shoulder arthroscopy for the throwing athlete. Tech Orthop 1988; 3:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/6\">",
"      Abrams JS. Special shoulder problems in the throwing athlete: pathology, diagnosis, and nonoperative management. Clin Sports Med 1991; 10:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/7\">",
"      Neer CS 2nd. Impingement lesions. Clin Orthop Relat Res 1983; :70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/8\">",
"      Hawkins RJ, Kennedy JC. Impingement syndrome in athletes. Am J Sports Med 1980; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/9\">",
"      Itoi E, Minagawa H, Yamamoto N, et al. Are pain location and physical examinations useful in locating a tear site of the rotator cuff? Am J Sports Med 2006; 34:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/10\">",
"      Gerber C, Galantay RV, Hersche O. The pattern of pain produced by irritation of the acromioclavicular joint and the subacromial space. J Shoulder Elbow Surg 1998; 7:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/11\">",
"      Reilly P, Macleod I, Macfarlane R, et al. Dead men and radiologists don't lie: a review of cadaveric and radiological studies of rotator cuff tear prevalence. Ann R Coll Surg Engl 2006; 88:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/12\">",
"      Sher JS, Uribe JW, Posada A, et al. Abnormal findings on magnetic resonance images of asymptomatic shoulders. J Bone Joint Surg Am 1995; 77:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/13\">",
"      Milgrom C, Schaffler M, Gilbert S, van Holsbeeck M. Rotator-cuff changes in asymptomatic adults. The effect of age, hand dominance and gender. J Bone Joint Surg Br 1995; 77:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/14\">",
"      Yamaguchi K, Ditsios K, Middleton WD, et al. The demographic and morphological features of rotator cuff disease. A comparison of asymptomatic and symptomatic shoulders. J Bone Joint Surg Am 2006; 88:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/15\">",
"      Fukuda H. Partial-thickness rotator cuff tears: a modern view on Codman's classic. J Shoulder Elbow Surg 2000; 9:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/16\">",
"      Gotoh M, Hamada K, Yamakawa H, et al. Interleukin-1-induced subacromial synovitis and shoulder pain in rotator cuff diseases. Rheumatology (Oxford) 2001; 40:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/17\">",
"      Moosmayer S, Smith HJ, Tariq R, Larmo A. Prevalence and characteristics of asymptomatic tears of the rotator cuff: an ultrasonographic and clinical study. J Bone Joint Surg Br 2009; 91:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/18\">",
"      Schibany N, Zehetgruber H, Kainberger F, et al. Rotator cuff tears in asymptomatic individuals: a clinical and ultrasonographic screening study. Eur J Radiol 2004; 51:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/19\">",
"      Kim HM, Teefey SA, Zelig A, et al. Shoulder strength in asymptomatic individuals with intact compared with torn rotator cuffs. J Bone Joint Surg Am 2009; 91:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/20\">",
"      Murrell GA, Walton JR. Diagnosis of rotator cuff tears. Lancet 2001; 357:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/21\">",
"      S&oslash;rensen AK, Bak K, Krarup AL, et al. Acute rotator cuff tear: do we miss the early diagnosis? A prospective study showing a high incidence of rotator cuff tears after shoulder trauma. J Shoulder Elbow Surg 2007; 16:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/22\">",
"      Wolff AB, Sethi P, Sutton KM, et al. Partial-thickness rotator cuff tears. J Am Acad Orthop Surg 2006; 14:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/23\">",
"      Rowan KR, Andrews G, Spielmann A, et al. MR shoulder arthrography in patients younger than 40 years of age: frequency of rotator cuff tear versus labroligamentous pathology. Australas Radiol 2007; 51:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/24\">",
"      Kane SM, Dave A, Haque A, Langston K. The incidence of rotator cuff disease in smoking and non-smoking patients: a cadaveric study. Orthopedics 2006; 29:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/25\">",
"      Wendelboe AM, Hegmann KT, Gren LH, et al. Associations between body-mass index and surgery for rotator cuff tendinitis. J Bone Joint Surg Am 2004; 86-A:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/26\">",
"      Park HB, Yokota A, Gill HS, et al. Diagnostic accuracy of clinical tests for the different degrees of subacromial impingement syndrome. J Bone Joint Surg Am 2005; 87:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/27\">",
"      Hegedus EJ, Goode A, Campbell S, et al. Physical examination tests of the shoulder: a systematic review with meta-analysis of individual tests. Br J Sports Med 2008; 42:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/28\">",
"      Hertel R, Ballmer FT, Lombert SM, Gerber C. Lag signs in the diagnosis of rotator cuff rupture. J Shoulder Elbow Surg 1996; 5:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/29\">",
"      Walch G, Boulahia A, Calderone S, Robinson AH. The 'dropping' and 'hornblower's' signs in evaluation of rotator-cuff tears. J Bone Joint Surg Br 1998; 80:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/30\">",
"      Scheibel M, Magosch P, Pritsch M, et al. The belly-off sign: a new clinical diagnostic sign for subscapularis lesions. Arthroscopy 2005; 21:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/31\">",
"      Keener JD, Wei AS, Kim HM, et al. Proximal humeral migration in shoulders with symptomatic and asymptomatic rotator cuff tears. J Bone Joint Surg Am 2009; 91:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/32\">",
"      Tuite MJ, Yandow DR, DeSmet AA, et al. Diagnosis of partial and complete rotator cuff tears using combined gradient echo and spin echo imaging. Skeletal Radiol 1994; 23:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/33\">",
"      Iannotti JP, Zlatkin MB, Esterhai JL, et al. Magnetic resonance imaging of the shoulder. Sensitivity, specificity, and predictive value. J Bone Joint Surg Am 1991; 73:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/34\">",
"      de Jesus JO, Parker L, Frangos AJ, Nazarian LN. Accuracy of MRI, MR arthrography, and ultrasound in the diagnosis of rotator cuff tears: a meta-analysis. AJR Am J Roentgenol 2009; 192:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/35\">",
"      Chun KA, Kim MS, Kim YJ. Comparisons of the various partial-thickness rotator cuff tears on MR arthrography and arthroscopic correlation. Korean J Radiol 2010; 11:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6887/abstract/36\">",
"      Omoumi P, Bafort AC, Dubuc JE, et al. Evaluation of rotator cuff tendon tears: comparison of multidetector CT arthrography and 1.5-T MR arthrography. Radiology 2012; 264:812.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 241 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-8AD9A5E0CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6887=[""].join("\n");
var outline_f6_46_6887=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND BIOMECHANICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Musculoskeletal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Magnetic resonance imaging (MRI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58593528\">",
"      Arthrography with MRI or CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/241|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/28/15814\" title=\"figure 1A\">",
"      Basic shoulder anatomy anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/60/28613\" title=\"figure 1B\">",
"      Basic shoulder anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/6/27748\" title=\"figure 1C\">",
"      Basic shoulder anatomy posterior view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/241|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/11/177\" title=\"picture 1\">",
"      Painful arc sign for rotator cuff pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/13/28882\" title=\"picture 2\">",
"      Test of shoulder external rotation strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/60/1987\" title=\"picture 3\">",
"      Jobes test of supraspinatus strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/27/19891\" title=\"picture 4\">",
"      Hawkins Kennedy test for shoulder impingement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/7/44149\" title=\"picture 5\">",
"      Neers test for shoulder impingement",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25095?source=related_link\">",
"      Management of rotator cuff tears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/53/29522?source=related_link\">",
"      Patient information: Rotator cuff injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=related_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27834?source=related_link\">",
"      Physical examination of the shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36425?source=related_link\">",
"      Radiologic evaluation of the painful shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_46_6888="C difficile colitis child";
var content_f6_46_6888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Contrast-enhanced computed tomography in 2 1/2-year-old with",
"    <em>",
"     Clostridium difficile",
"    </em>",
"    colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 2 1/2-year-old boy with an ill-defined congenital arthrogryposis syndrome and developmental delay developed diarrhea. Over a three-week period, his illness progressed to include 6 to 12 stools per day, abdominal tenderness, mild abdominal distension, fever to 39.4&deg;C, and fecal occult blood. The dose of a proton pump inhibitor for gastroesophageal reflux had been increased within two weeks prior to onset, and he had received courses of cefdinir and azithromycin for minor respiratory infections. At admission, polymorphonuclear neutrophil count was 6670/&micro;L, and band count was 14,330/&micro;L. Hemoglobin was 10.5 g. Albumin and globulin were both low at 2.4 g/dL and 2.2 g/dL, respectively. Fecal",
"    <em>",
"     C. difficile",
"    </em>",
"    toxin A/B enzyme immunoassay was positive in two successive samples. Computed tomography (above) demonstrated findings consistent with severe",
"    <em>",
"     C. difficile",
"    </em>",
"    disease, including colonic wall thickening (panels A, B, C), dilated colon (panel C), and accordion sign (panels A, C). He was admitted to the intensive care unit and treated with oral vancomycin and intravenous metronidazole for two weeks, with clearance of fecal toxin on the second day of treatment and gradual resolution of symptoms. He had two subsequent, progressively milder, toxin-positive relapses, which were treated with tapering courses of vancomycin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Radiographs courtesy of Brian Green, MD, University of Missouri Health Care.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6888=[""].join("\n");
var outline_f6_46_6888=null;
var title_f6_46_6889="Nutritional assessment in chronic liver disease";
var content_f6_46_6889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nutritional assessment in chronic liver disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6889/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6889/contributors\">",
"     Puneeta Tandon, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6889/contributors\">",
"     Leah Gramlich, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6889/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6889/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6889/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6889/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/46/6889/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein calorie malnutrition (PCM) has been described in 50 to 100 percent of patients with decompensated cirrhosis and at least 20 percent with compensated cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. PCM is associated with a number of complications including development of variceal bleeding and ascites, increased surgical morbidity and mortality, reduced survival, and (in some studies) worsening hepatic function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/2,6-12\">",
"     2,6-12",
"    </a>",
"    ]. Patients with cirrhosis (particularly those with advanced disease) may also have micronutrient deficiencies. Recognition of macro- and micronutrient deficiencies is important since supplemental nutrition has been associated with a reduction in the risk of infection and in-hospital mortality and improved liver function parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF MALNUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of malnutrition in cirrhosis is multifactorial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/5\">",
"     5",
"    </a>",
"    ]. Protein, carbohydrate, and lipid metabolism are all affected by liver disease. Contributing factors include inadequate dietary intake, impaired digestion and absorption, and altered metabolism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anorexia, nausea, encephalopathy, gastritis, ascites, a sodium restricted diet and concurrent alcohol consumption can all contribute to a reduction in dietary intake.",
"     </li>",
"     <li>",
"      Malabsorption and maldigestion of nutrients can result from bile salt deficiency, bacterial overgrowth, altered intestinal motility, portal hypertensive changes to the intestine, mucosal injury, and increased intestinal permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/17-21\">",
"       17-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cirrhosis represents an accelerated state of starvation and as such, fuels other than glucose (protein, lipids) are used [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is an overall loss of protein from reduced synthesis of urea and hepatic proteins, reduced intestinal protein absorption, and increased urinary nitrogen excretion. Liver disease is associated with a lowered ratio of branched-chain to aromatic amino acids.",
"     </li>",
"     <li>",
"      Abnormal carbohydrate metabolism is associated with insulin resistance, impaired gluconeogenesis and reduced glycogen stores. As a result, lipids are preferentially oxidized for energy and the respiratory quotient (RQ) is less than in patients without chronic liver disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. The RQ is defined as the ratio of the volume of CO2 production to the volume of O2 consumption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies on the effect of chronic liver disease on the resting energy expenditure have mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. One study suggested that energy expenditure in patients with cirrhosis was similar to controls after adjusting for body surface area [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast, a cross-sectional study of 473 patients with cirrhosis found that 34 percent had hypermetabolism as measured by indirect calorimetry [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/31\">",
"     31",
"    </a>",
"    ]. The increase in resting energy expenditure correlated with lean body mass but not with the severity or type of liver disease and was, in part, attributed to an increase in beta-adrenergic activity. Other studies have demonstrated that hypermetabolism persists at least one year after liver transplant and correlates with a reduction in survival [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has also been suggested that ascites may contribute to an increase in energy expenditure and that its removal results in a significant reduction in the REE as measured by indirect calorimetry [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/28\">",
"     28",
"    </a>",
"    ]. The mechanism underlying this observation is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GOALS OF NUTRITIONAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of a nutritional assessment is to identify nutritional risk that influences morbidity and mortality and which may be modifiable with targeted nutritional therapy. Nutritional assessment allows for a determination of the macronutrient (energy, protein, water) and micronutrient (electrolytes, minerals, vitamins, trace elements) state of a given individual. Body composition and muscle function analysis add supplemental information.",
"   </p>",
"   <p>",
"    There is no gold standard for the assessment of nutritional status in patients with cirrhosis. It is not practical to attempt detailed nutritional assessment in all patients. We suggest a staged approach, beginning with a complete history and physical examination and proceeding with more detailed testing if needed.",
"   </p>",
"   <p>",
"    As a general rule, patients with compensated cirrhosis are more likely to be similar to a healthy population clinically and on laboratory investigations compared with those with decompensated cirrhosis. Thus, nutritional assessment is generally more detailed in patients with decompensated disease. However, many standard nutritional assessment tools have limitations when applied to patients with decompensated cirrhosis due to the presence of salt and water retention and advanced hepatic synthetic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several key features should be evaluated in all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Weight history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be questioned about their usual weight, recent weight loss (over two weeks), and percentage of usual weight lost over six months. Unintentional weight loss of &gt;10 percent over six months is considered severe. Although useful in compensated cirrhosis, the weight history is less accurate in patients with decompensated cirrhosis because of salt and water retention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dietary intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food intake can be assessed by the 24 hour dietary recall. The patient recounts meals and snacks on a typical day, intake of food from each of the food groups, and the use of nutritional supplements. Although the specific foods do not have to be documented in the chart, the process does assist with an overall appraisal of adequate balanced intake. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23175?source=see_link\">",
"     \"Dietary and nutritional assessment in adults\"",
"    </a>",
"    .) Alcohol intake should also be quantified since it can limit the intake of food calories in alcoholic patients. Other barriers to intake in patients with cirrhosis, especially those who have decompensated cirrhosis, include anorexia, nausea, sodium restriction, and gastroesophageal reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastrointestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration and frequency of comorbidities that may impact nutritional status, such as nausea, vomiting, diarrhea, and steatorrhea should be assessed. Symptoms that persist for more than two weeks and which are associated with a limitation in nutrient intake are concerning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nature and severity of liver disease should be categorized using standard techniques such as the Child Pugh score, Model for end-stage liver disease score (MELD), or designation of compensated versus decompensated liver disease. The presence of ascites is one of the earliest features of decompensation. Standard nutritional assessment tools are limited by sodium and water retention and with advancing hepatic synthetic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Micronutrient deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Features suggestive of micronutrient deficiency should be sought. These include dermatitis (zinc, vitamin A, niacin), night blindness or photophobia (vitamin A), burning of the mouth or tongue (vitamin B12, folate), easy bruising (vitamin C, K), and paresthesias (thiamine, pyridoxine).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest performing a general physical examination with additional focus given to physical findings supportive of macro- or micronutrient deficiency.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Self-reported weights can be inaccurate. Thus, we obtain a total body weight on a standard scale and use it to determine body mass index (BMI). The presence of pedal edema and ascites should be recorded with each weight measurement since weight fluctuates with salt and water retention.",
"     </li>",
"     <li>",
"      We evaluate patients for the presence of ankle or sacral edema, ascites, muscle wasting (as determined in the quadriceps and deltoids), and loss of subcutaneous fat (as determined in the triceps and chest).",
"     </li>",
"     <li>",
"      We examine patients for features supportive of micronutrient deficiency such as pallor (iron deficiency), hyperkeratosis (vitamin A), dermatitis (vitamin A), bruising (vitamin C, vitamin K), glossitis (vitamin B12, folate, niacin), angular stomatitis (vitamin B12), and reduced lower extremity deep tendon reflexes (vitamins B12, B1) (",
"      <a class=\"graphic graphic_table graphicRef78426 \" href=\"UTD.htm?1/19/1341\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUBJECTIVE GLOBAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standardized batteries of questions and physical examination findings have been evaluated for nutritional assessment. An example is the subjective global assessment tool (SGA), which can be administered at the bedside and includes a focused history and physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The historical components of the SGA include weight loss, change in dietary intake, presence of gastrointestinal symptoms, functional capacity and the metabolic demand associated with the disease state. Physical examination components include the presence of edema, ascites, muscle wasting, and subcutaneous fat loss. The presence of muscle wasting and subcutaneous fat loss is suggestive of severe malnutrition. Components are combined to obtain an SGA rating ranging from well-nourished to severely malnourished.",
"   </p>",
"   <p>",
"    The inter-rater reliability of a modified SGA was assessed in a study of 20 liver transplant candidates; raters agreed on the nutritional status of patients 80 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/36\">",
"     36",
"    </a>",
"    ]. Muscle wasting and fat depletion were the best predictors of the final SGA score.",
"   </p>",
"   <p>",
"    The sensitivity of the SGA in cirrhotics has been questioned in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. For example, a study that included predominantly Child Pugh A patients suggested that the standard SGA did not perform as well as assessment of handgrip strength (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Anthropometry'",
"    </a>",
"    below) in predicting complications of cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study of 79 cirrhotics (60 percent Child Pugh B or C) estimated the prevalence of malnutrition as 32 percent by the SGA (6 percent of Child A, 35 percent of Child B, and 72 percent of Child C) compared with 60 percent by body composition analysis (34 percent of Child A, 69 percent of Child B, 94 percent of Child C) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/38\">",
"     38",
"    </a>",
"    ]. However, whether body composition analysis represents a gold-standard is unclear since the authors did not report clinical outcomes. In addition, 2 of 17 control patients were classified as being malnourished by body composition analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SGA correlates with post-operative outcomes in patients without cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Its accuracy in predicting outcomes in patients with cirrhosis is unsettled [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/37,38,40-42\">",
"     37,38,40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variation on the SGA, the Royal Free Hospital Global Assessment (RFH GA) tool, incorporates the body mass index, mid-arm muscle circumference measurements, and details of dietary intake to classify individuals as adequately nourished, moderately malnourished, or severely malnourished [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/43\">",
"     43",
"    </a>",
"    ]. The RFH GA classification has differences between sexes. When compared with body composition data, it only significantly correlates with the depletion of total body protein stores or fat free mass in men, but not in women. Furthermore, the relationship between nutritional status and survival is significant in men, but not in women. In addition to clarifying its utility in women, these findings require external validation before the RFH GA can be used routinely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We obtain a serum albumin, creatinine and INR in patients with compensated cirrhosis. Although these measures are still obtained in decompensated cirrhotics, they are affected by hepatic synthetic dysfunction and therefore are less likely to be independent markers of nutritional status. We obtain additional tests in special populations (eg, alcoholics, those with clinically evident malnutrition or micronutrient deficiency, cholestatic liver disease or anemia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Plasma proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several plasma proteins have been used to assess nutritional status such as albumin, pre-albumin, transferrin and coagulation factors (as measured by the prothrombin time or international normalized ratio). These proteins are synthesized in the liver and thus their deficiency can reflect either malnutrition or hepatic synthetic dysfunction. As a result, their assessment may be more helpful in early cirrhosis. Two small studies comparing plasma proteins to anthropometric measures (triceps skinfold thickness, arm muscle circumference) found a poor correlation in patients with advanced cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=see_link\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The half-life of the plasma proteins should also be considered when using them for nutritional assessment. The long half-life of albumin",
"    <span class=\"nowrap\">",
"     (t1/2",
"    </span>",
"    ~20 days) makes it less reflective of acute changes in nutritional status while the relatively short half-life of pre-albumin",
"    <span class=\"nowrap\">",
"     (t1/2",
"    </span>",
"    ~2 to 3 days) makes it easily influenced by intercurrent illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fat soluble vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced alcoholic liver disease and cholestatic liver disease (primary biliary cirrhosis) commonly have fat soluble vitamin deficiency. We routinely check plasma levels of vitamins A, D, E and obtain an INR in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Water soluble vitamins and minerals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water soluble vitamin deficiency, especially thiamine is common in alcoholic liver disease. However, a targeted search for treatable micronutrient deficiencies (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , zinc, vitamin B12, folate) can be considered in patients considered to be at high nutritional risk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Plasma levels are a reasonable surrogate marker of body stores. In patients with alcoholic liver disease, we routinely advise daily multivitamin intake. In patients with anemia, we obtain serum levels of folate and vitamin B12 and iron studies (depending upon characteristics of the anemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with chronic liver disease, including viral hepatitis, cirrhosis, and hepatocellular carcinoma, may have elevated serum vitamin B12 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/48\">",
"     48",
"    </a>",
"    ]. Vitamin B12 is stored in the liver and may be released during hepatic cytolysis. In addition, decreased vitamin B12 clearance may contribute to elevated levels. However, before attributing an elevated vitamin B12 level to chronic liver disease, other causes of an elevated serum B12 level, such as chronic myelogenous leukemia, promyelocytic leukemia, polycythemia vera, and the hypereosinophilic syndrome, should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Delayed hypersensitivity and total lymphocyte count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of the delayed hypersensitivity skin test and total lymphocyte count are affected by multiple factors including cirrhosis. Thus, these are considered unreliable markers of nutritional status in chronic liver disease and we do not routinely check them [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creatinine is a marker of lean tissue (protein) stores. Cirrhosis is associated with reduced hepatic creatine synthesis, decreased muscle mass, and increased tubular creatinine secretion. Because of these limitations, the validity measures based upon creatinine (such as urinary creatinine and the creatinine height index) as markers of nutritional status in cirrhotics is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/6,49\">",
"     6,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANCILLARY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple nutritional assessment tools have been assessed in patients with cirrhosis. We do not routinely use nutritional assessment tools beyond the history and physical examination, SGA and laboratory investigations. These tools may be considered on an individual basis in those with evidence of malnutrition, although the subgroup of malnourished patients that may be missed by standard techniques has not been defined clearly. Referral to a dietitian experienced in patient with chronic liver disease can be helpful in those considered to be malnourished by standard assessment and those in whom nutritional status is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Anthropometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the composition of body compartments (water, fat, muscle) occur with liver disease and correlate with adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Anthropometry is a bedside tool used to assess body fat and lean tissue stores that is largely unaffected by salt and water overload that indirectly estimates body composition. In our experience, malnutrition is almost universally present and clinically obvious in patients with cirrhosis who have severe decompensation. Although anthropometry correlates with mortality in these patients, the subgroup in which anthropometric tools may, if at all, improve the detection of malnutrition above and beyond history, physical examination and the SGA has not been well-defined.",
"   </p>",
"   <p>",
"    Mid-arm muscle circumference (MAMC) is a marker of lean tissue stores. It incorporates both the mid-arm circumference (measured at the midpoint between the acromion and olecranon in the non-dominant arm) and skin-fold thickness. Skin-fold thickness (SFT) is used commonly to estimate fat reserve. The triceps skin fold thickness is measured by a caliper at the midpoint between the acromion and olecranon. For all of these measures, a value lower than the fifth percentile is considered diagnostic of severe malnutrition. Reference values used for this were established from the general population in 1981 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/52\">",
"     52",
"    </a>",
"    ]. Interobserver variability can be minimized by using a single trained observer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/6\">",
"     6",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Several studies have correlated these measures with a reference standard and with survival in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/41,53-57\">",
"     41,53-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 69 patients with cirrhosis (88 percent Child Pugh class A) evaluated the correlation of MAMC (and other anthropometric markers) with body cell mass depletion (BCM) using isotope dilution [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/53\">",
"       53",
"      </a>",
"      ]. BCM is an established marker of protein calorie malnutrition in chronic liver disease and correlates with the development of nutritional complications [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/1,29,58,59\">",
"       1,29,58,59",
"      </a>",
"      ]. The authors concluded that MAMC and handgrip strength were the best predictors of BCM depletion. A mid-arm muscle circumference of &lt;23 centimeters in combination with a handgrip strength of &lt;30 kilograms had a sensitivity of 94 percent and negative predictive value of 97 percent. By contrast, the SGA, weight-height measurement, triceps skinfold thickness, and",
"      <span class=\"nowrap\">",
"       biochemical/hematologic",
"      </span>",
"      parameters did not correlate well with BCM.",
"     </li>",
"     <li>",
"      The accuracy of skin fold thickness was estimated in a study that included 40 patients with cirrhosis without ascites (60 percent Child Pugh A) who were evaluated with a DEXA scan and skin fold measurements of the triceps, biceps, subscapular and suprailiac areas [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/54\">",
"       54",
"      </a>",
"      ]. The results of both investigations were similar, suggesting that four site skin fold measurements could be used to estimate body fat in patients without ascites.",
"     </li>",
"     <li>",
"      Studies assessing the relationship between anthropometric measures and survival have shown mixed results [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/55-57\">",
"       55-57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Miscellaneous tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several more specialized investigations such as the dual energy X-ray absorptiometry (DEXA) scan, deuterium oxide dilution, in vivo neutron activation analysis, and bioelectrical impedance analysis have also been studied. The main limitation of these investigations is their cost and limited availability. As a result, we do not routinely incorporate these tools into the assessment of nutritional status in our patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Bioelectrical impedance analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bioelectrical impedance analysis (BIA) is performed by applying electrodes to one arm and one leg or by standing on a special scale. Impedance is proportional to the length of the conductor and inversely related to the cross-sectional area of the conductor. Accuracy in placement of electrodes is essential because even small variations can cause relatively large errors in the measurement of impedance and corresponding errors in the estimate of body water. A variety of formulas have been developed to convert the impedance, which measures body water, into an estimate of fat. Studies evaluating its accuracy in patients with cirrhosis have been mixed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18789?source=see_link\">",
"     \"Determining body composition in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study focusing on 41 patients with cirrhosis (20 with and 21 without ascites) compared results of BIA with mid-arm circumference (MAMC), triceps skinfold thickness (TSFT), and urinary creatinine excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/60\">",
"     60",
"    </a>",
"    ]. Total body potassium counting (TBP) was used as a reference standard for body cell mass. Although TSFT, MAMC, and urinary creatinine excretion correlated well with BIA in controls and cirrhotics without ascites, no correlation was found in cirrhotics with ascites. When compared to TBP, BIA was superior to TSFT, MAMC and urinary creatinine excretion in patients with cirrhosis. The correlation of BIA with TBP in patients with ascites was lower but still significant. However, other studies found BIA to be less accurate in both compensated and decompensated cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Dual energy X-ray absorptiometry (DEXA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;DEXA accurately estimates fat mass in patients with liver disease but does not provide as accurate an assessment of lean body mass [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. This inaccuracy is most likely related to the increase in extracellular water in patients with decompensated liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/3,66\">",
"     3,66",
"    </a>",
"    ]. DEXA retains utility in the diagnosis of osteoporosis and osteomalacia, particularly in patients with cholestatic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/67\">",
"     67",
"    </a>",
"    ]. The AGA technical review for osteoporosis in hepatic disorders, as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Deuterium oxide dilution in vivo neutron activation analysis (IVNAA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deuterium oxide dilution can be used to accurately assess total body water while the IVNAA can be used to accurately assess total body protein. However, these techniques are labor intensive and not routinely available [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Muscle function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have confirmed the importance of muscle strength as a predictive factor for malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/53,68,69\">",
"     53,68,69",
"    </a>",
"    ]. The measurement of muscle strength requires a handgrip dynamometer and is not currently part of routine nutritional status evaluation. In the study described above [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/37\">",
"     37",
"    </a>",
"    ], hand-grip strength (result below mean &plusmn; 2 standard deviations) was a more sensitive predictor of malnutrition and the only method that was able to predict major complications (uncontrolled ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome) at one year. The limitations of this study are that the SGA was used as the gold standard to obtain sensitivity, specificity and predictive values for handgrip strength. In addition, 88 percent of patients were Child Pugh A and thus results may not be generalizable to those with more advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ENERGY EXPENDITURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Part of the assessment of nutritional needs requires an estimation of resting energy expenditure (REE), which can be assessed using standard formulas such as the Harris Benedict equation.",
"   </p>",
"   <p>",
"    The accuracy of the Harris Benedict equation (HBE) in determining REE is subject to variability based upon the factors that make up the equation (weight, height, age, gender). The use of ideal body weight tends to underestimate energy requirements whereas the use of an actual weight may overestimate them. In one study comparing the HBE to indirect calorimetry, the HBE underestimated the mean energy requirements using either the actual or corrected (ideal) body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/70\">",
"     70",
"    </a>",
"    ]. Several other studies have noted underestimation of mean energy requirements of up to 18 percent using this and other prediction methods [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/7,22,29\">",
"     7,22,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gold standard for the assessment of REE is indirect calorimetry [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/7\">",
"     7",
"    </a>",
"    ]. We do not do this routinely in all patients but instead reserve it for patients who do not meet nutritional expectations despite compliance with nutritional therapy. Indirect calorimetry may also be relevant in determining energy requirements for individuals with a BMI &lt;20 in whom estimates from the HBE may be incorrect and in whom the implications of inappropriate feeding are more likely to have a negative impact on outcome.",
"   </p>",
"   <p>",
"    An assessment of 268 patients with cirrhosis (34 percent Child Pugh A) evaluated resting energy expenditure (indirect calorimetry), muscle function (using grip strength and a respiratory pressure transducer), and body composition (using neutron activation analysis and dual-energy X-ray absorptiometry) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/71\">",
"     71",
"    </a>",
"    ]. The following summarizes the major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant protein depletion was more common in men than in women (63 versus 28 percent) and occurred in half of all patients. These sex differences in metabolism require further study.",
"     </li>",
"     <li>",
"      Protein depletion was more common as Child Pugh class increased and correlated with a reduction in muscle function.",
"     </li>",
"     <li>",
"      Hypermetabolism was identified in 15 percent of patients, a lower percentage than in previous studies. It was not associated with protein depletion, gender, severity or cause of liver disease, or concurrent ascites or tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74885317\">",
"    <span class=\"h1\">",
"     NUTRITION GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional intervention is required in patients who are found to be malnourished. We refer such patients to a dietitian. General guidelines have been developed to guide nutrition management in patients with chronic liver disease. We agree with the guidelines from the European Society for Clinical Nutrition and Metabolism (ESPEN) that were issued in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6889/abstract/72\">",
"     72",
"    </a>",
"    ]. What follows is a summary of those guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74885353\">",
"    <span class=\"h2\">",
"     Alcoholic steatohepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ESPEN guidelines make the following suggestions for patients with alcoholic steatohepatitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use simple bedside methods such as the Subjective Global Assessment (SGA) or anthropometry to identify patients at risk of undernutrition (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Subjective global assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Anthropometry'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Energy intake of 35 to 40",
"      <span class=\"nowrap\">",
"       kcal/kg/day",
"      </span>",
"      (147-168",
"      <span class=\"nowrap\">",
"       kJ/kg/day)",
"      </span>",
"     </li>",
"     <li>",
"      Protein intake of 1.2 to 1.5",
"      <span class=\"nowrap\">",
"       g/kg/day",
"      </span>",
"     </li>",
"     <li>",
"      Use of supplementary enteral nutrition (preferably oral supplements) when patients cannot meet their caloric requirements with normal food",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Whole protein formulas are generally recommended",
"     </li>",
"     <li>",
"      Consider using more concentrated high-energy formulas in patients with ascites",
"     </li>",
"     <li>",
"      Use branch chain amino acid (BCAA)-enriched formulas in patients with hepatic encephalopathy arising during enteral nutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use tube feeding if patients are not able to maintain adequate oral intake",
"     </li>",
"     <li>",
"      Percutaneous endoscopic gastrostomy (PEG) tube placement is associated with a higher risk of complications and is not recommended",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74885369\">",
"    <span class=\"h2\">",
"     Cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ESPEN guidelines make the following suggestions for patients with cirrhosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use simple bedside methods such as the SGA or anthropometry to identify patients at risk of undernutrition",
"     </li>",
"     <li>",
"      Use bioelectric impedance analysis to quantitate undernutrition, despite some limitations in patients with ascites (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Bioelectrical impedance analysis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Energy intake of 35 to 40",
"      <span class=\"nowrap\">",
"       kcal/kg/day",
"      </span>",
"      (147-168",
"      <span class=\"nowrap\">",
"       kJ/kg/day)",
"      </span>",
"     </li>",
"     <li>",
"      Protein intake of 1.2 to 1.5",
"      <span class=\"nowrap\">",
"       g/kg/day",
"      </span>",
"     </li>",
"     <li>",
"      Use of supplementary enteral nutrition when patients cannot meet their caloric requirements with normal food",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Whole protein formulas are generally recommended",
"     </li>",
"     <li>",
"      Consider using more concentrated high-energy formulas in patients with ascites",
"     </li>",
"     <li>",
"      Use BCAA-enriched formulas in patients with hepatic encephalopathy arising during enteral nutrition; the use of oral BCAA supplements can improve clinical outcomes in advanced cirrhosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of tube feeding if patients are not able to maintain adequate oral intake",
"     </li>",
"     <li>",
"      PEG tube placement is associated with a higher risk of complications and is not recommended",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74885377\">",
"    <span class=\"h2\">",
"     Transplantation and surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations for patients prior to transplantation or surgery are the same as those for patients with cirrhosis. The following suggestions apply to patients following transplantation or surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use simple bedside methods such as the SGA or anthropometry to identify patients at risk of undernutrition",
"     </li>",
"     <li>",
"      Use bioelectric impedance analysis to quantitate undernutrition, despite some limitations in patients with ascites",
"     </li>",
"     <li>",
"      Initiate normal",
"      <span class=\"nowrap\">",
"       food/enteral",
"      </span>",
"      nutrition within 12 to 24 hours after liver transplantation",
"     </li>",
"     <li>",
"      Initiate early normal food or enteral nutrition after other surgical procedures",
"     </li>",
"     <li>",
"      Energy intake of 35 to 40",
"      <span class=\"nowrap\">",
"       kcal/kg/day",
"      </span>",
"      (147-168",
"      <span class=\"nowrap\">",
"       kJ/kg/day)",
"      </span>",
"     </li>",
"     <li>",
"      Protein intake of 1.2 to 1.5",
"      <span class=\"nowrap\">",
"       g/kg/day",
"      </span>",
"     </li>",
"     <li>",
"      Use nasogastric tubes or catheter jejunostomy for early enteral nutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Whole protein formulas are generally recommended",
"     </li>",
"     <li>",
"      In patients with ascites, concentrated high-energy formulas are preferred due to issues with fluid balance",
"     </li>",
"     <li>",
"      Use BCAA-enriched formulas in patients with hepatic encephalopathy arising during enteral nutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protein calorie and micronutrient deficiencies are common in patients with cirrhosis, particularly in those with advanced disease. Sex differences in protein energy malnutrition described in some reports require further study.",
"     </li>",
"     <li>",
"      The assessment of nutritional status in patients with decompensated cirrhosis is challenging because of volume and sodium shifts, hepatic synthetic dysfunction and changes in energy metabolism.",
"     </li>",
"     <li>",
"      We suggest that all patients with cirrhosis undergo a history and physical examination focusing on weight history, dietary intake, gastrointestinal symptoms, severity of liver disease and signs and symptoms of micronutrient deficiencies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We also suggest more formal nutritional assessment with the subjective global assessment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Subjective global assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We obtain a serum albumin, creatinine, and INR in patients with compensated cirrhosis. Although these measures are still obtained in patients with decompensated cirrhosis, they are affected by hepatic synthetic dysfunction and therefore are less likely to be independent markers of nutritional status. We obtain additional tests in special populations (eg, alcoholics, those with clinically evident malnutrition or micronutrient deficiency, cholestatic liver disease or anemia). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other specialized investigations, including the bioelectrical impedance analysis, dual energy X-ray absorptiometry (DEXA) scan, deuterium oxide dilution and in vivo neutron activation analysis are not measured routinely. Muscle strength, classically measured by handgrip strength, is a promising and sensitive predictor of malnutrition but further studies are needed.",
"     </li>",
"     <li>",
"      In patients requiring nutritional intervention, we suggest calculating resting energy expenditure (REE) to estimate caloric requirements (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We initially use prediction equations such as the Harris Benedict equation, recognizing that they can underestimate the REE. Indirect calorimetry is reserved for situations where despite compliance to an estimated nutrient prescription, the patient is not making the expected nutritional gains. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Energy expenditure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines can be used to guide nutritional intervention in patients with chronic liver disease. (See",
"      <a class=\"local\" href=\"#H74885317\">",
"       'Nutrition guidelines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/1\">",
"      Crawford DH, Shepherd RW, Halliday JW, et al. Body composition in nonalcoholic cirrhosis: the effect of disease etiology and severity on nutritional compartments. Gastroenterology 1994; 106:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/2\">",
"      Lautz HU, Selberg O, K&ouml;rber J, et al. Protein-calorie malnutrition in liver cirrhosis. Clin Investig 1992; 70:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/3\">",
"      DiCecco SR, Wieners EJ, Wiesner RH, et al. Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation. Mayo Clin Proc 1989; 64:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/4\">",
"      Hehir DJ, Jenkins RL, Bistrian BR, Blackburn GL. Nutrition in patients undergoing orthotopic liver transplant. JPEN J Parenter Enteral Nutr 1985; 9:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/5\">",
"      Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol 2012; 10:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/6\">",
"      Siriboonkoom W, Gramlich L. Nutrition and chronic liver disease. Can J Gastroenterol 1998; 12:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/7\">",
"      Plauth M, Merli M, Kondrup J, et al. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 1997; 16:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/8\">",
"      M&oslash;ller S, Bendtsen F, Christensen E, Henriksen JH. Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. J Hepatol 1994; 21:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/9\">",
"      Porayko MK, DiCecco S, O'Keefe SJ. Impact of malnutrition and its therapy on liver transplantation. Semin Liver Dis 1991; 11:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/10\">",
"      Shaw BW Jr, Wood RP, Gordon RD, et al. Influence of selected patient variables and operative blood loss on six-month survival following liver transplantation. Semin Liver Dis 1985; 5:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/11\">",
"      Manguso F, D'Ambra G, Menchise A, et al. Effects of an appropriate oral diet on the nutritional status of patients with HCV-related liver cirrhosis: a prospective study. Clin Nutr 2005; 24:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/12\">",
"      Cabr&eacute; E, Gassull MA. Nutritional and metabolic issues in cirrhosis and liver transplantation. Curr Opin Clin Nutr Metab Care 2000; 3:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/13\">",
"      Cabre E, Gonzalez-Huix F, Abad-Lacruz A, et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 1990; 98:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/14\">",
"      de L&eacute;dinghen V, Beau P, Mannant PR, et al. Early feeding or enteral nutrition in patients with cirrhosis after bleeding from esophageal varices? A randomized controlled study. Dig Dis Sci 1997; 42:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/15\">",
"      Kearns PJ, Young H, Garcia G, et al. Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology 1992; 102:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/16\">",
"      Fan ST, Lo CM, Lai EC, et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/17\">",
"      Vlahcevic ZR, Buhac I, Farrar JT, et al. Bile acid metabolism in patients with cirrhosis. I. Kinetic aspects of cholic acid metabolism. Gastroenterology 1971; 60:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/18\">",
"      Bode JC. Alcohol and the gastrointestinal tract. Ergeb Inn Med Kinderheilkd 1980; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/19\">",
"      Bode C, Bode JC. Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol 2003; 17:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/20\">",
"      Dinda PK, Leddin DJ, Beck IT. Histamine is involved in ethanol-induced jejunal microvascular injury in rabbits. Gastroenterology 1988; 95:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/21\">",
"      Sarfeh IJ, Aaronson S, Lombino D, et al. Selective impairment of nutrient absorption from intestines with chronic venous hypertension. Surgery 1986; 99:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/22\">",
"      Charlton MR. Alcoholic Liver Disease: Energy and Protein Metabolism in Alcoholic Liver Disease. Clin Liver Dis 1998; 2:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/23\">",
"      Owen OE, Trapp VE, Reichard GA Jr, et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J Clin Invest 1983; 72:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/24\">",
"      Merli M, Riggio O, Romiti A, et al. Basal energy production rate and substrate use in stable cirrhotic patients. Hepatology 1990; 12:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/25\">",
"      Shanbhogue RL, Bistrian BR, Jenkins RL, et al. Resting energy expenditure in patients with end-stage liver disease and in normal population. JPEN J Parenter Enteral Nutr 1987; 11:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/26\">",
"      Jhangiani SS, Agarwal N, Holmes R, et al. Energy expenditure in chronic alcoholics with and without liver disease. Am J Clin Nutr 1986; 44:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/27\">",
"      Schneeweiss B, Graninger W, Ferenci P, et al. Energy metabolism in patients with acute and chronic liver disease. Hepatology 1990; 11:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/28\">",
"      Dolz C, Raurich JM, Ib&aacute;&ntilde;ez J, et al. Ascites increases the resting energy expenditure in liver cirrhosis. Gastroenterology 1991; 100:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/29\">",
"      M&uuml;ller MJ, Lautz HU, Plogmann B, et al. Energy expenditure and substrate oxidation in patients with cirrhosis: the impact of cause, clinical staging and nutritional state. Hepatology 1992; 15:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/30\">",
"      Pierrugues R, Blanc P, Daures JP, Michel H. Relationship of resting energy expenditure with liver function and nutritional status in patients with alcoholic cirrhosis. Nutrition 1992; 8:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/31\">",
"      M&uuml;ller MJ, B&ouml;ttcher J, Selberg O, et al. Hypermetabolism in clinically stable patients with liver cirrhosis. Am J Clin Nutr 1999; 69:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/32\">",
"      Selberg O, B&ouml;ttcher J, Tusch G, et al. Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 1997; 25:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/33\">",
"      M&uuml;ller MJ, Loyal S, Schwarze M, et al. Resting energy expenditure and nutritional state in patients with liver cirrhosis before and after liver transplantation. Clin Nutr 1994; 13:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/34\">",
"      Detsky AS, Baker JP, Mendelson RA, et al. Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: methodology and comparisons. JPEN J Parenter Enteral Nutr 1984; 8:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/35\">",
"      Nutritional status in cirrhosis. Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. J Hepatol 1994; 21:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/36\">",
"      Hasse J, Strong S, Gorman MA, Liepa G. Subjective global assessment: alternative nutrition-assessment technique for liver-transplant candidates. Nutrition 1993; 9:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/37\">",
"      Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition 2005; 21:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/38\">",
"      Figueiredo FA, Perez RM, Freitas MM, Kondo M. Comparison of three methods of nutritional assessment in liver cirrhosis: subjective global assessment, traditional nutritional parameters, and body composition analysis. J Gastroenterol 2006; 41:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/39\">",
"      Moriwaki H. Nutritional assessment in liver cirrhosis. J Gastroenterol 2006; 41:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/40\">",
"      Stephenson GR, Moretti EW, El-Moalem H, et al. Malnutrition in liver transplant patients: preoperative subjective global assessment is predictive of outcome after liver transplantation. Transplantation 2001; 72:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/41\">",
"      Gunsar F, Raimondo ML, Jones S, et al. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther 2006; 24:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/42\">",
"      Roongpisuthipong C, Sobhonslidsuk A, Nantiruj K, Songchitsomboon S. Nutritional assessment in various stages of liver cirrhosis. Nutrition 2001; 17:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/43\">",
"      Morgan MY, Madden AM, Soulsby CT, Morris RW. Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis. Hepatology 2006; 44:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/44\">",
"      Merli M, Romiti A, Riggio O, Capocaccia L. Optimal nutritional indexes in chronic liver disease. JPEN J Parenter Enteral Nutr 1987; 11:130S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/45\">",
"      Piquet MA, Ollivier I, Gloro R, et al. Nutritional indices in cirrhotic patients. Nutrition 2006; 22:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/46\">",
"      Nielsen K, Kondrup J, Martinsen L, et al. Long-term oral refeeding of patients with cirrhosis of the liver. Br J Nutr 1995; 74:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/47\">",
"      Hirsch S, Bunout D, de la Maza P, et al. Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis. JPEN J Parenter Enteral Nutr 1993; 17:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/48\">",
"      Ermens AA, Vlasveld LT, Lindemans J. Significance of elevated cobalamin (vitamin B12) levels in blood. Clin Biochem 2003; 36:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/49\">",
"      Nielsen K, Kondrup J, Martinsen L, et al. Nutritional assessment and adequacy of dietary intake in hospitalized patients with alcoholic liver cirrhosis. Br J Nutr 1993; 69:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/50\">",
"      Prijatmoko D, Strauss BJ, Lambert JR, et al. Early detection of protein depletion in alcoholic cirrhosis: role of body composition analysis. Gastroenterology 1993; 105:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/51\">",
"      Mendenhall CL, Tosch T, Weesner RE, et al. VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 1986; 43:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/52\">",
"      Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr 1981; 34:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/53\">",
"      Figueiredo FA, Dickson ER, Pasha TM, et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl 2000; 6:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/54\">",
"      Fiore P, Merli M, Andreoli A, et al. A comparison of skinfold anthropometry and dual-energy X-ray absorptiometry for the evaluation of body fat in cirrhotic patients. Clin Nutr 1999; 18:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/55\">",
"      Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/56\">",
"      Abad-Lacruz A, Cabr&eacute; E, Gonz&aacute;lez-Huix F, et al. Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child-Pugh score in nonbleeding advanced cirrhotics. Am J Gastroenterol 1993; 88:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/57\">",
"      Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology 1996; 23:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/58\">",
"      Pierson RN Jr, Wang J, Thornton JC, Heymsfield SB. The quality of the body cell mass--1996. Are we ready to measure it? Appl Radiat Isot 1998; 49:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/59\">",
"      Suhr O, Danielsson A, Rydh A, et al. Impact of gastrointestinal dysfunction on survival after liver transplantation for familial amyloidotic polyneuropathy. Dig Dis Sci 1996; 41:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/60\">",
"      Pirlich M, Sch&uuml;tz T, Spachos T, et al. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology 2000; 32:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/61\">",
"      Guglielmi FW, Contento F, Laddaga L, et al. Bioelectric impedance analysis: experience with male patients with cirrhosis. Hepatology 1991; 13:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/62\">",
"      Zillikens MC, van den Berg JW, Wilson JH, Swart GR. Whole-body and segmental bioelectrical-impedance analysis in patients with cirrhosis of the liver: changes after treatment of ascites. Am J Clin Nutr 1992; 55:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/63\">",
"      Madden AM, Morgan MY. A comparison of skinfold anthropometry and bioelectrical impedance analysis for measuring percentage body fat in patients with cirrhosis. J Hepatol 1994; 21:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/64\">",
"      McCullough AJ, Mullen KD, Kalhan SC. Measurements of total body and extracellular water in cirrhotic patients with and without ascites. Hepatology 1991; 14:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/65\">",
"      Addolorato G, Capristo E, Greco AV, et al. Three months of abstinence from alcohol normalizes energy expenditure and substrate oxidation in alcoholics: a longitudinal study. Am J Gastroenterol 1998; 93:2476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/66\">",
"      Falck-Ytter Y, McCullough AJ. The effect of alcohol on body composition. Am J Gastroenterol 2000; 95:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/67\">",
"      Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/68\">",
"      Mendenhall CL, Moritz TE, Roselle GA, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. JPEN J Parenter Enteral Nutr 1995; 19:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/69\">",
"      Andersen H, Borre M, Jakobsen J, et al. Decreased muscle strength in patients with alcoholic liver cirrhosis in relation to nutritional status, alcohol abstinence, liver function, and neuropathy. Hepatology 1998; 27:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/70\">",
"      Madden AM, Morgan MY. Resting energy expenditure should be measured in patients with cirrhosis, not predicted. Hepatology 1999; 30:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/71\">",
"      Peng S, Plank LD, McCall JL, et al. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study. Am J Clin Nutr 2007; 85:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6889/abstract/72\">",
"      Plauth M, Cabr&eacute; E, Riggio O, et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006; 25:285.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3598 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-8189A37D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6889=[""].join("\n");
var outline_f6_46_6889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS OF MALNUTRITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GOALS OF NUTRITIONAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Weight history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dietary intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastrointestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Micronutrient deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUBJECTIVE GLOBAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Plasma proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fat soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Water soluble vitamins and minerals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Delayed hypersensitivity and total lymphocyte count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Creatinine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANCILLARY TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Anthropometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Miscellaneous tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Bioelectrical impedance analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Dual energy X-ray absorptiometry (DEXA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Deuterium oxide dilution in vivo neutron activation analysis (IVNAA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Muscle function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ENERGY EXPENDITURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74885317\">",
"      NUTRITION GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74885353\">",
"      Alcoholic steatohepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74885369\">",
"      Cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74885377\">",
"      Transplantation and surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3598\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3598|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/19/1341\" title=\"table 1\">",
"      Signs of nutritional deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18789?source=related_link\">",
"      Determining body composition in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23175?source=related_link\">",
"      Dietary and nutritional assessment in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_46_6890="Mucormycosis (zygomycosis)";
var content_f6_46_6890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mucormycosis (zygomycosis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6890/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6890/contributors\">",
"     Gary M Cox, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6890/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6890/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/46/6890/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/46/6890/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/46/6890/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucormycosis is manifested by a variety of different syndromes in humans, particularly in immunocompromised patients and those with diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/1\">",
"     1",
"    </a>",
"    ]. Devastating rhino-orbital-cerebral and pulmonary infections are the most common syndromes caused by these fungi.",
"   </p>",
"   <p>",
"    There is some controversy over the terminology used to refer to infections due to this group of fungi. The term \"mucormycosis\" was used for years and then was supplanted by \"zygomycosis\" for several decades. Based on molecular studies, \"mucormycosis\" is currently again the appropriate term [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiology, clinical manifestations, diagnosis, and therapy of mucormycosis will be reviewed here. Several specific syndromes that can be caused by these fungi are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=see_link\">",
"     \"Fungal rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37849?source=see_link\">",
"     \"Non-access related infections in chronic dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYCOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genera in the order Mucorales cause most human infection. These organisms are ubiquitous in nature, and can be found on decaying vegetation and in the soil. These fungi grow rapidly and release large numbers of spores that can become airborne. Because the agents of mucormycosis are common in the environment, they are relatively frequent contaminants in the clinical microbiology laboratory; all humans have ample exposure to these fungi during day-to-day activities. The fact that mucormycosis is a rare human infection reflects the effectiveness of the intact human immune system. This is further supported by the finding that almost all human infections due to the agents of mucormycosis occur in the presence of some underlying compromising condition.",
"   </p>",
"   <p>",
"    The genera most commonly found in human infections are Rhizopus, Mucor, and Rhizomucor; Cunninghamella, Absidia, Saksenaea, and Apophysomyces are genera that are less commonly implicated in infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hyphae of the Mucorales are distinct and allow for a presumptive identification from clinical specimens. The hyphae are broad (5 to 15 micron diameter), irregularly branched, and have rare septations (",
"    <a class=\"graphic graphic_picture graphicRef66476 \" href=\"UTD.htm?4/58/5030\">",
"     picture 1",
"    </a>",
"    ). This is in contrast to the hyphae of ascomycetous molds, such as Aspergillus, which are narrower (2 to 5 micron diameter), exhibit regular branching, and have many septations.",
"   </p>",
"   <p>",
"    The lack of regular septations may contribute to the fragile nature of the hyphae and the difficulty of growing the agents of mucormycosis from clinical specimens. Grinding clinical specimens can cause excessive damage to the hyphae. Thus, finely mincing tissues is preferred for culturing tissue samples that may contain molds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhizopus organisms have an enzyme, ketone reductase, which allows them to thrive in high glucose, acidic conditions. Serum from healthy individuals inhibits growth of Rhizopus, whereas serum from individuals in diabetic ketoacidosis stimulates growth [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rhino-orbital-cerebral and pulmonary mucormycosis are acquired by the inhalation of spores. In healthy individuals, cilia transport these spores to the pharynx and they are cleared through the gastrointestinal tract. In susceptible individuals, infection usually begins in the nasal turbinates or the alveoli [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/7\">",
"     7",
"    </a>",
"    ]. The agents of mucormycosis are angioinvasive; thus, infarction of infected tissues is a hallmark of invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Deferoxamine and iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     Deferoxamine",
"    </a>",
"    , which chelates both iron and aluminum, increases the risk of mucormycosis by enhancing growth and pathogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/7,9-11\">",
"     7,9-11",
"    </a>",
"    ]. The deferoxamine-iron chelate, called feroxamine, is a siderophore for the species Rhizopus, increasing iron uptake by the fungus, which stimulates fungal growth and leads to tissue invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/8,12\">",
"     8,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iron overload itself may predispose to mucormycosis in the absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, individuals with diabetic ketoacidosis have elevated concentrations of free iron in their serum, which supports the grown of Rhizopus oryzae at an acidic, but not at an alkaline, pH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     Deferoxamine",
"    </a>",
"    was once used commonly as an aluminum chelator in patients with renal failure; however, aluminum excess is rarely seen today. Currently, patients at risk for deferoxamine-associated mucormycosis are those who have received multiple blood transfusions and are treated with this chelating agent for iron overload. The majority of patients with deferoxamine-associated infection present with disseminated disease that is rapidly fatal, with a mortality rate that approaches 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link&amp;anchor=H16#H16\">",
"     \"Aluminum toxicity in end-stage renal disease\", section on 'Mucormycosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    , other iron chelating agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    , do not act as siderophores and therefore do not increase the risk of mucormycosis. To the contrary, studies in mice with mucormycosis found that these agents might actually be beneficial (eg, improve survival and reduce the tissue fungal burden) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The use of deferasirox for the treatment of mucormycosis has not been adequately studied in humans. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Deferasirox'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients with invasive mucormycosis have some underlying disease that both predisposes to the infection and influences the clinical presentation. The most common underlying diseases are [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5,18-29\">",
"     5,18-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes mellitus, particularly with ketoacidosis",
"     </li>",
"     <li>",
"      Treatment with glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hematologic malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/1,27,30\">",
"       1,27,30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hematopoietic stem cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5,25,31\">",
"       5,25,31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Solid organ transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/31-34\">",
"       31-34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/9-11,13\">",
"       9-11,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Iron overload [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acquired immunodeficiency syndrome (AIDS)",
"     </li>",
"     <li>",
"      Injection drug use",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Trauma/burns",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Deferoxamine and iron overload'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link\">",
"     \"Chelation therapy for iron overload states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368730430\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of mucormycosis is difficult to estimate, since it is not a reportable disease and the risk varies widely in different populations. A review of 929 cases of mucormycosis that were reported between 1940 and 2003 noted that diabetes was the most common risk factor, found in 36 percent of cases, followed by hematologic malignancies (17 percent), and solid organ or hematopoietic cell transplantation (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5\">",
"     5",
"    </a>",
"    ]. In some patients, mucormycosis was the diabetes-defining illness. In a later study of 101 patients diagnosed with mucormycosis between 2005 and 2007 in France, hematologic malignancy was the most common risk factor, occurring in 50 percent of patients, followed by diabetes in 23 percent, and trauma in 18 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368730437\">",
"    <span class=\"h2\">",
"     Malignancy and hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with malignancy, hematologic malignancies are much more frequently associated with mucormycosis than solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5,25-27\">",
"     5,25-27",
"    </a>",
"    ]. However, even in patients with hematologic malignancies, mucormycosis appears to occur in fewer than 1 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/36\">",
"     36",
"    </a>",
"    ]. Among hematopoietic cell transplant (HCT) recipients, the reported incidence has ranged from 0.1 to 2 percent, with the highest incidence in patients with graft-versus-host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports from several countries have noted an increase in mucormycosis in patients with hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/1,30,37\">",
"     1,30,37",
"    </a>",
"    ]. Most of these patients had undergone HCT, many had graft-versus-host disease, and almost all were on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    for prophylaxis or treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/1,30\">",
"     1,30",
"    </a>",
"    ]. A case-control study in a population of patients with hematologic malignancies compared patients with mucormycosis to those who had no fungal infection; voriconazole prophylaxis was an independent risk factor for mucormycosis (odds ratio 10.4, 95% CI 2.1-39) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the possible causes of the increase in mucormycosis in patients with hematologic malignancies continue to be debated, reasons that have been proposed include selection of the agents of mucormycosis caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    use, increasing use and intensity of immunosuppressive agents, and a decrease in invasive aspergillosis-related mortality following HCT resulting in the emergence of rare fungi during the late post-transplant period [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368730444\">",
"    <span class=\"h2\">",
"     Solid organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a multicenter prospective study of invasive fungal infections in transplant recipients in the United States between 2001 and 2006, the 12-month cumulative incidence of mucormycosis was less than 1 percent among solid organ transplant recipients; only 2 percent of invasive fungal infections in such patients were caused by the agents of mucormycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/31,39\">",
"     31,39",
"    </a>",
"    ]. Among solid organ transplant recipients, risk factors for mucormycosis include renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/32\">",
"     32",
"    </a>",
"    ], renal failure, diabetes, and prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368730458\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, diabetes is a common predisposing condition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5\">",
"     5",
"    </a>",
"    ]. The number of reported cases of mucormycosis in diabetic patients in the United States has declined since the 1990s, a trend that has not been noted in France [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/37\">",
"     37",
"    </a>",
"    ] or in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/28,40\">",
"     28,40",
"    </a>",
"    ]. One hypothesis that has been suggested to explain the decline in the United States is the widespread use of statins, which have inhibitory activity in vitro against a wide range of the agents of mucormycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695986708\">",
"    <span class=\"h2\">",
"     Healthcare-associated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare-associated cases of mucormycosis have been reported. In a study of 169 healthcare-associated cases of mucormycosis in Europe between 1970 and 2008, the major underlying diseases were solid organ transplantation (in 24 percent), diabetes mellitus (in 22 percent), and severe prematurity (in 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/41\">",
"     41",
"    </a>",
"    ]. Skin was the most common site of infection (in 57 percent), followed by the gastrointestinal tract (15 percent). Portals of entry included surgery, catheters (especially intravascular catheters), and adhesive tape. Outbreaks and clusters have been associated with adhesive bandages, wooden tongue depressors, and adjacent building construction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695986953\">",
"    <span class=\"h2\">",
"     Natural disaster-associated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of mucormycosis have occurred following a tornado, a tsunami, and a volcanic eruption [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. As an example, in 2011, an outbreak of necrotizing soft-tissue infections causes by Apophysomyces trapeziformis occurred in patients with traumatic injuries resulting from a tornado in Joplin, Missouri in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/42\">",
"     42",
"    </a>",
"    ]. A total of 18 suspected cases were identified, of which 13 were confirmed. Two patients had diabetes and none were immunocompromised. Ten patients required intensive care unit admission, and five died.",
"   </p>",
"   <p>",
"    In a case-control study of patients injured during the tornado in Joplin, Missouri, the 13 patients with confirmed infection each had a median of 5 wounds (range 1 to 7); 11 patients (85 percent) had &ge;1 fracture, 9 patients (69 percent) had blunt trauma, and 5 patients (38 percent) had penetrating trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/45\">",
"     45",
"    </a>",
"    ]. All case patients had been located in the zone that sustained the most severe damage during the tornado. On multivariate analysis, infection was associated with penetrating trauma (adjusted odds ratio [aOR] 8.8, 95% CI 1.1-69.2) and an increased number of wounds (aOR 2.0 for each additional wound; 95% CI 1.2-3.2). Whole genome sequencing showed that the Apophysomyces trapeziformis isolates represented four separate strains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244297312\">",
"    <span class=\"h2\">",
"     Combat-associated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive fungal infections, including mucormycosis, have been reported in United States military personnel who sustained blast injuries during combat in Afghanistan [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/46\">",
"     46",
"    </a>",
"    ]. Between June 2009 through December 2010, a total of 37 cases were identified, including 20 proven cases (with histopathologic evidence of angioinvasion), 4 probable cases (with histopathologic evidence of nonvascular tissue invasion), and 13 possible cases (with a positive fungal culture, but without histopathologic evidence). All injuries occurred secondary to explosive blasts and most injuries occurred during foot patrol (in 34 patients; 92 percent). All patients had extremity injuries and 29 patients (78 percent) had lower extremity amputation either at the time of the injury or during the first surgery following the injury. Thirty-six patients (97 percent) required large volume blood transfusion. Mold isolates were recovered from the wounds of 31 patients (83 percent); the most commonly detected fungi belonged to the order Mucorales (in 16 patients), Aspergillus spp (in 16 patients), and Fusarium spp (in 9 patients). Multiple mold species were isolated from 28 percent of infected wounds. Frequent debridements or amputation revisions were required and three deaths were thought to be related to the infection (8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucormycosis is characterized by infarction and necrosis of host tissues that results from invasion of the vasculature by hyphae [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/29\">",
"     29",
"    </a>",
"    ]. The pace is usually fast, but there are rare descriptions of infections with an indolent course [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rhino-orbital-cerebral mucormycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical presentation of mucormycosis is rhino-orbital-cerebral infection, which is presumed to start with inhalation of spores into the paranasal sinuses of a susceptible host. Hyperglycemia, usually with an associated metabolic acidosis, is the most common underlying condition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5\">",
"     5",
"    </a>",
"    ]. A review of 179 cases of rhino-orbital-cerebral mucormycosis found that 126 (70 percent) of the patients had diabetes mellitus, and most had ketoacidosis at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/18\">",
"     18",
"    </a>",
"    ]. There are rare reports of rhino-orbital-cerebral mucormycosis in the absence of any apparent risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/18,48-51\">",
"     18,48-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The infection usually presents as acute sinusitis with fever, nasal congestion, purulent nasal discharge, headache, and sinus pain. All of the sinuses become involved and spread to contiguous structures, such as the palate, orbit and brain, usually progresses rapidly. However, there have been some reports of rhino-orbital-cerebral mucormycosis with an indolent course [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hallmarks of spread beyond the sinuses are tissue necrosis of the palate resulting in palatal eschars, destruction of the turbinates, perinasal swelling, and erythema and cyanosis of the facial skin overlying the involved sinuses. A black eschar, which results from necrosis of tissues after vascular invasion by the fungus, may be visible in the nasal mucosa or the palate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs of orbital involvement include periorbital edema, proptosis, and blindness. Facial numbness is frequent and results from infarction of sensory branches of the fifth cranial nerve. Spread of the infection from the ethmoid sinus to the frontal lobe results in obtundation. Spread from the sphenoid sinuses to the adjacent cavernous sinus can result in cranial nerve palsies, thrombosis of the sinus, and involvement of the carotid artery. Hematogenous spread to other organs is rare unless the patient has an underlying hematologic malignancy with neutropenia.",
"   </p>",
"   <p>",
"    A review of 208 cases of rhino-orbital-cerebral mucormycosis published in the literature between 1970 and 1993 found the following frequency of symptoms and signs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever &mdash; 44 percent",
"     </li>",
"     <li>",
"      Nasal ulceration or necrosis &mdash; 38 percent",
"     </li>",
"     <li>",
"      Periorbital or facial swelling &mdash; 34 percent",
"     </li>",
"     <li>",
"      Decreased vision &mdash;30 percent",
"     </li>",
"     <li>",
"      Ophthalmoplegia &mdash; 29 percent",
"     </li>",
"     <li>",
"      Sinusitis &mdash; 26 percent",
"     </li>",
"     <li>",
"      Headache &mdash; 25 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rhino-orbital-cerebral mucormycosis is most commonly caused by Rhizopus oryzae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary mucormycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary mucormycosis is a rapidly progressive infection that occurs after inhalation of spores into the bronchioles and alveoli (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71447 \" href=\"UTD.htm?1/43/1713\">",
"     image 1",
"    </a>",
"    ). Pneumonia with infarction and necrosis results, and the infection can spread to contiguous structures, such as the mediastinum and heart [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] or disseminate hematogenously to other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients have fever with hemoptysis that can sometimes be massive [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The most common underlying conditions have been hematologic malignancies, treatment with glucocorticoids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    , and solid organ transplantation; pulmonary infection is less common than rhino-orbital-cerebral infection in diabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/19,56-61\">",
"     19,56-61",
"    </a>",
"    ]. In a series of 24 patients with mucormycosis and hematologic malignancy, 71 percent had pulmonary involvement and only one had rhino-orbital-cerebral involvement; 7 of 12 patients who underwent autopsy had disseminated disease in addition to pulmonary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gastrointestinal mucormycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although unusual, mucormycosis of the gastrointestinal tract may occur as the result of ingestion of spores. One review of 87 cases found that the stomach was the most common site (58 percent), followed by the colon (32 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/62\">",
"     62",
"    </a>",
"    ]. The ileum and esophagus were rare sites of involvement.",
"   </p>",
"   <p>",
"    The underlying diseases of patients with gastrointestinal mucormycosis have been diabetes mellitus, solid organ transplantation, treatment with glucocorticoids, and prematurity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    malnutrition in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/20,62-64\">",
"     20,62-64",
"    </a>",
"    ]. Patients present with abdominal pain and hematemesis. The gastrointestinal lesions are necrotic ulcers that can lead to perforation and peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/20\">",
"     20",
"    </a>",
"    ]. Bowel infarctions and hemorrhagic shock can result from gastrointestinal mucormycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/65\">",
"     65",
"    </a>",
"    ], and the prognosis for all patients is poor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cutaneous mucormycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of the skin and soft tissues with the agents of mucormycosis usually results from inoculation of the spores into the dermis. Thus, cutaneous mucormycosis is almost always associated with trauma or wounds. The entry of the fungi into the dermis can result from seemingly innocuous insults, such as the entry site for an intravenous catheter, spider bites, and insulin injection sites [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/21,22,66-70\">",
"     21,22,66-70",
"    </a>",
"    ]. Infection has also been associated with contaminated traumatic wounds, dressings and splints, burns, and surgical sites [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/21,22,41-43,45,46,66-70\">",
"     21,22,41-43,45,46,66-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When infection is associated with relatively minor breaks in the skin, the host usually has some underlying disease, such as diabetes mellitus, organ transplantation, neutropenia, or severe prematurity. Infections associated with major trauma or contaminated dressings have been found in otherwise immunocompetent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5,70\">",
"     5,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthcare-associated, natural disaster-associated, and combat-associated cases of mucormycosis are discussed above. (See",
"    <a class=\"local\" href=\"#H695986708\">",
"     'Healthcare-associated'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H695986953\">",
"     'Natural disaster-associated'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H244297312\">",
"     'Combat-associated'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cutaneous mucormycosis usually appears as a single, painful, indurated area of cellulitis that develops into an ecthyma-like lesion. Patients who have suffered trauma with an open wound that was contaminated with spores can develop rapidly progressive tissue necrosis reflecting the presence of ischemic infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/21,22,43,45,46,67,69,70\">",
"     21,22,43,45,46,67,69,70",
"    </a>",
"    ]. Dissemination and deep tissue involvement are unusual complications of cutaneous mucormycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/68,70\">",
"     68,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Renal mucormycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated involvement of the kidneys with mucormycosis has been reported and is presumed to occur via seeding of the kidneys during an episode of fungemia. Almost all patients with isolated renal mucormycosis have risk factors for fungemia, including an intravenous catheter, intravenous drug use, or AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/23,24,71-73\">",
"     23,24,71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with renal mucormycosis usually present with flank pain and fever. Involvement can be either unilateral or bilateral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Isolated CNS involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) mucormycosis typically arises from an adjacent paranasal sinus infection. However, there have been more than 30 cases of isolated CNS mucormycosis described in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/24,74-76\">",
"     24,74-76",
"    </a>",
"    ]. Infection was thought to result from seeding of the brain during an episode of fungemia, analogous to renal involvement. Over two-thirds of the patients with isolated CNS mucormycosis have been intravenous drug users who presumably have injected material contaminated with fungi directly into the bloodstream. Some of the patients with isolated CNS mucormycosis had HIV infection in addition to drug use. However, it is not clear whether HIV infection is an independent risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/24,75,77\">",
"     24,75,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the patients presented with lethargy and focal neurologic deficits, with the vast majority having involvement of the basal ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Isolated involvement of the frontal lobe has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Disseminated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated mucormycosis is rare, and occurs most commonly in severely immunocompromised patients, burn patients, premature infants, and individuals who have received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. In the series of 929 cases of mucormycosis described above, disseminated disease was present in 40 to 50 percent of patients with cerebral or pulmonary mucormycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5\">",
"     5",
"    </a>",
"    ]. The mortality rate in patients with disseminated mucormycosis was 96 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of mucormycosis relies upon the identification of organisms in tissue by histopathology with culture confirmation. However, culture often yields no growth, and histopathologic identification of an organism with a structure typical of Mucorales may provide the only evidence of infection. A clinician must think of this entity in the appropriate clinical setting and pursue invasive testing in order to establish a diagnosis as early as possible.",
"   </p>",
"   <p>",
"    Investigational studies have demonstrated the feasibility of using polymerase chain reaction (PCR)-based techniques on histologic specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. In one study of patients with proven mucormycosis, among 12 cases that were positive by culture, 10 were also positive by PCR and sequencing was concordant with culture results to the genus level in 9 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/79\">",
"     79",
"    </a>",
"    ]. Among 15 culture-negative cases, PCR was positive and sequencing allowed genus identification in 12. The PCR-based technique used in this study appears promising for establishing the diagnosis of mucormycosis when cultures are negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Rhino-orbital-cerebral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of mucormycosis should be suspected in high risk patients, especially those who have diabetes and metabolic acidosis and who present with sinusitis, altered mentation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infarcted tissue in the nose or palate.",
"   </p>",
"   <p>",
"    Endoscopic evaluation of the sinuses should be performed to look for tissue necrosis and to obtain specimens. The specimens should be inspected for characteristic broad, non-septate hyphae with right-angle branching using calcofluor white and methenamine silver stains. The presence of the characteristic hyphae in a clinical specimen provides a presumptive diagnosis that should prompt further evaluation (",
"    <a class=\"graphic graphic_picture graphicRef66476 \" href=\"UTD.htm?4/58/5030\">",
"     picture 1",
"    </a>",
"    ). However, the absence of hyphae should not dissuade clinicians from the diagnosis of mucormycosis when the clinical picture is highly suggestive.",
"   </p>",
"   <p>",
"    Further evaluation includes imaging of the head with either computed tomography (CT) or magnetic resonance imaging (MRI) to gauge sinus involvement and to evaluate contiguous structures such as the eyes and brain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pulmonary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pulmonary mucormycosis is difficult since the presentation does not differ from pneumonia due to other angioinvasive molds. Chest radiographs or CT scans may demonstrate focal consolidation, masses, pleural effusions, or multiple nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/58,82\">",
"     58,82",
"    </a>",
"    ]. A halo sign (ground glass attenuation surrounding a nodule) is characteristic of angioinvasive fungi, but a reversed halo sign, a focal area of ground glass attenuation surrounded by a ring of consolidation, has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Mucormycosis appears to be the most common condition to cause the reversed halo sign in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/84\">",
"     84",
"    </a>",
"    ]. In a retrospective study that included 189 patients with proven or probable fungal pneumonia, the reversed halo sign was seen in 7 of 37 patients with mucormycosis (19 percent), 1 of 132 patients with invasive aspergillosis (&lt;1 percent), and none of 20 patients with fusariosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/83\">",
"     83",
"    </a>",
"    ]. Radiographic evidence of infarction with cavitary lesions and an air crescent sign is unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/58\">",
"     58",
"    </a>",
"    ]. In a series of 45 cases, the following radiographic features were independent predictors of mucormycosis and helped to differentiate it from aspergillosis: concomitant sinusitis, &gt;10 pulmonary nodules on CT scan, pleural effusion, and prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sputum or bronchoalveolar lavage (BAL) specimens can show the characteristic broad non-septate hyphae, which is often the first indicator of mucormycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/59\">",
"     59",
"    </a>",
"    ]. However, in one case series, only 25 percent of sputum or BAL specimens were positive premortem [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/25\">",
"     25",
"    </a>",
"    ]. Hyphae can also be demonstrated on lung biopsy (",
"    <a class=\"graphic graphic_picture graphicRef66476 \" href=\"UTD.htm?4/58/5030\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of gastrointestinal mucormycosis can be made with endoscopic biopsy of the lesions that show the characteristic hyphae. For isolated renal involvement, percutaneous biopsy or nephrectomy can establish a diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/23\">",
"     23",
"    </a>",
"    ]. Urine cultures are almost always sterile. Imaging of the kidneys with ultrasound or CT can demonstrate enhancement and small foci suggestive of abscesses. In isolated CNS involvement, CT scan usually shows poorly-enhancing lesions; cerebrospinal fluid cultures are negative. Diagnosis can be made with biopsy or resection of the involved areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of mucormycosis involves a combination of surgical debridement of involved tissues and antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elimination of predisposing factors for infection, such as hyperglycemia, metabolic acidosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    administration, immunosuppressive drugs, and neutropenia, is also critical. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (lipid formulation) is the drug of choice. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    is used as step-down therapy for patients who have responded to amphotericin B and rarely as salvage therapy for patients who don't respond to or cannot tolerate amphotericin B.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive surgical debridement of involved tissues should be undertaken as soon as the diagnosis of rhino-orbital-cerebral mucormycosis is suspected. The debridement to remove all necrotic tissue will often be disfiguring, requiring removal of the palate, nasal cartilages, and the orbit. There are reports of patients with early pulmonary infection who were cured with lobectomies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/56,57,85\">",
"     56,57,85",
"    </a>",
"    ]. However, many patients present with multilobar involvement that precludes surgical resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antifungal drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early initiation of antifungal therapy improves the outcome of infection with mucormycosis. This was illustrated in a retrospective study of 70 patients with hematologic malignancy who had mucormycosis in which delayed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    therapy (starting treatment &ge;6 days after diagnosis) resulted in an almost twofold increase in mortality at 12 weeks after diagnosis (83 versus 49 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most clinicians use a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    in order to deliver a high dose with less nephrotoxicity. The usual starting dose is 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    , and many clinicians will increase the dose up as high as 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily in an attempt to control this infection. The total dosage of lipid amphotericin B that should be administered has not been studied.",
"   </p>",
"   <p>",
"    There have been apparent cures of isolated renal mucormycosis using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate alone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/23,71\">",
"     23,71",
"    </a>",
"    ] or combined with nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/23\">",
"     23",
"    </a>",
"    ]. In severe cases in which there is little residual renal function, nephrectomy with a short course of amphotericin B deoxycholate (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for one to two weeks) appears to be a reasonable course of action.",
"   </p>",
"   <p>",
"    Although the echinocandins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ) have no in vitro activity against the agents of mucormycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/87-89\">",
"     87-89",
"    </a>",
"    ], Rhizopus oryzae, the most common cause of mucormycosis, expresses the target enzyme for echinocandins, suggesting that these agents may have clinical utility [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/90\">",
"     90",
"    </a>",
"    ]. In a retrospective study of 21 patients with rhino-orbital mucormycosis and 20 patients with rhino-orbital-cerebral mucormycosis, all six patients who received combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and an echinocandin had successful outcomes, defined as surviving and not requiring hospice care, compared with only 14 of 31 patients who received amphotericin B monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/91\">",
"     91",
"    </a>",
"    ]. The benefit of combination therapy was most pronounced among patients with cerebral involvement; all four patients who received combination therapy survived compared with 4 of 16 patients who received amphotericin B monotherapy.",
"   </p>",
"   <p>",
"    However, there are several limitations to the above observations. In addition to the limited number of patients, all underwent surgical debridement, making it difficult to assess the impact of antifungal therapy on outcomes. The patients who received an echinocandin were seen more recently than most of those who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    alone. In addition, the patients were predominantly nonneutropenic. This may have influenced the response to antifungal therapy because modulation of the host neutrophil response is postulated to occur when echinocandins are used to treat infections with filamentous fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At this time, larger studies are needed to establish whether combination therapy is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/94\">",
"     94",
"    </a>",
"    ]. We do not recommend using the combination of a polyene and an echinocandin for the treatment of mucormycosis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    is a broad-spectrum oral azole agent that is active in vitro against the agents of mucormycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. The clinical efficacy of posaconazole was shown in a salvage study that enrolled 91 patients who had failed or could not tolerate standard therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/97\">",
"     97",
"    </a>",
"    ]. Posaconazole led to complete or partial response in 60 percent of patients; 21 percent had stable disease. Although there are limitations to this salvage study, this series supports a potential role for posaconazole for the treatment of mucormycosis refractory to standard therapy.",
"   </p>",
"   <p>",
"    For patients who have responded to a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    is an option for oral step-down therapy. We continue amphotericin B until the patient has shown signs of improvement; this usually takes several weeks. The optimal dosing of posaconazole is 200 mg four times daily, given with fatty food to enhance absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. In patients who cannot take posaconazole four times daily, 400 mg twice daily can be given (also with fatty food). A serum trough concentration of posaconazole should be checked after one week of therapy; we suggest a goal trough concentration &ge;0.7",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H30#H30\">",
"     \"Pharmacology of azoles\", section on 'Posaconazole'",
"    </a>",
"    ). Until an intravenous formulation is made available, posaconazole should not be used for initial therapy of mucormycosis.",
"   </p>",
"   <p>",
"    Other antifungal agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    , are not effective against the Mucorales (",
"    <a class=\"graphic graphic_table graphicRef82439 \" href=\"UTD.htm?29/34/30254\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/95\">",
"     95",
"    </a>",
"    ]. Hyperbaric oxygen has been used in some patients with mucormycosis, but the benefit of this therapy has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/53,100,101\">",
"     53,100,101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616017815\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, patients can be switched from a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    for oral step-down therapy once a favorable clinical response has been achieved, which usually takes several weeks.",
"   </p>",
"   <p>",
"    Therapy should continue until there is clinical resolution of the signs and symptoms of infection, as well as resolution of radiographic signs of active disease; therapy should also continue until reversal of underlying immunosuppression has been achieved, when feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/102\">",
"     102",
"    </a>",
"    ]. Therapy often extends for months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Deferasirox",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the iron chelator,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    , which increases the risk of mucormycosis, the oral iron chelating agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    , showed a possible benefit when used to treat mucormycosis in murine models. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Deferoxamine and iron overload'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The possible utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    as an adjunctive therapy for mucormycosis has been evaluated in small studies, with mixed results. In an open label study of deferasirox in combination with antifungal therapy, seven of eight patients survived [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/103\">",
"     103",
"    </a>",
"    ]. In a small trial, 20 patients with proven or probable mucormycosis were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    plus either deferasirox or placebo for the first 14 days of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/104\">",
"     104",
"    </a>",
"    ]. Death at 90 days after therapy was initiated was significantly more frequent in those who received deferasirox than in those who received placebo (82 versus 22 percent). Reported adverse events were similar between the groups. One possible reason for the worse outcomes in the patients who received deferasirox is that more patients with hematologic malignancy, neutropenia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary involvement received this agent; all of these conditions are associated with poor outcomes. Further study is necessary to determine the possible benefits or harms of deferasirox.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite early diagnosis and aggressive combined surgical and medical therapy, the prognosis for recovery from mucormycosis is poor (",
"    <a class=\"graphic graphic_table graphicRef82439 \" href=\"UTD.htm?29/34/30254\">",
"     table 1",
"    </a>",
"    ). An exception is cutaneous involvement, which rarely disseminates. Independent risk factors for mortality include disseminated infection, renal failure, and infection with Cunninghamella species, while the use of surgery and administration of any antifungal agent were associated with a better outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Rhino-orbital-cerebral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of 208 patients with rhino-orbital-cerebral infection showed that the most significant factors associated with death were delayed diagnosis, the presence of",
"    <span class=\"nowrap\">",
"     hemiparesis/hemiplegia,",
"    </span>",
"    bilateral sinus involvement, leukemia, renal disease, and treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/53\">",
"     53",
"    </a>",
"    ]. Overall mortality from rhino-orbital-cerebral mucormycosis ranges from 25 to 62 percent, with the best prognosis in patients with infection confined to the sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5\">",
"     5",
"    </a>",
"    ]. The prognosis is especially poor for patients with brain, cavernous sinus, or carotid involvement, although some patients with these complications have been cured of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/105-107\">",
"     105-107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pulmonary mucormycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome in patients with pulmonary mucormycosis is worse than for patients with rhino-orbital-cerebral involvement, with mortality rates as high as 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5,32,56\">",
"     5,32,56",
"    </a>",
"    ]. This may be in part due to the underlying conditions and to the inability to widely excise the involved tissues. Widely disseminated mucormycosis carries a mortality rate of 90 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/46/6890/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucormycosis is manifested by a variety of syndromes in humans, particularly in immunocompromised patients and those with diabetes mellitus. Devastating rhino-orbital-cerebral and pulmonary infections are the major syndromes caused by these fungi. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Organisms in the Order Mucorales are ubiquitous in nature, and can be found on decaying vegetation and in the soil. The genera most commonly found in human infections are Rhizopus, Mucor, and Rhizomucor; Cunninghamella, Saksenaea, and Apophysomyces are genera that are less commonly implicated in infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mycology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       Deferoxamine",
"      </a>",
"      , which chelates both iron and aluminum, increases the risk of mucormycosis by enhancing growth and pathogenicity. The deferoxamine-iron chelate, called feroxamine, is a siderophore for the species Rhizopus, increasing iron uptake by the fungus, which stimulates fungal growth and leads to tissue invasion. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Deferoxamine and iron overload'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mucormycosis is characterized by infarction and necrosis of host tissues that results from invasion of the vasculature by hyphae. The most common clinical presentation of mucormycosis is rhino-orbital-cerebral infection, which is presumed to start with inhalation of spores into the paranasal sinuses of a susceptible host. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Rhino-orbital-cerebral mucormycosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary mucormycosis is a rapidly progressive infection that occurs after inhalation of spores into the bronchioles and alveoli. Pneumonia with infarction and necrosis results, and the infection can spread to contiguous structures such as the mediastinum and heart or disseminate hematogenously to other organs. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pulmonary mucormycosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mucormycosis can also cause gastrointestinal, cutaneous, renal, and disseminated disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of mucormycosis relies upon the identification of organisms in tissue by histopathology with culture confirmation. However, culture often yields no growth, and histopathologic identification of an organism with a structure typical of Mucorales may provide the only evidence of infection. A clinician must think of this entity in the appropriate clinical setting and pursue invasive testing in order to establish a diagnosis as early as possible. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of mucormycosis involves a combination of surgical debridement of involved tissues and antifungal therapy. Elimination of predisposing factors for infection, such as hyperglycemia, metabolic acidosis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      administration, and neutropenia, is also critical. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (lipid formulation) is the drug of choice. Most clinicians use a lipid formulation of amphotericin B in order to deliver a high dose with less nephrotoxicity. The usual starting dose is 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"       amphotericin B lipid complex",
"      </a>",
"      , and many clinicians will increase the dose up as high as 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily in an attempt to control this infection. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      is used as step-down therapy for patients who have responded to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      and rarely as salvage therapy for patients who don't respond to or cannot tolerate amphotericin B. Therapy should continue until all signs of infection have resolved and until reversal of underlying immunosuppression has been achieved when feasible, and often extends for months. The optimal dosing of posaconazole is 200 mg four times daily, given with fatty food to enhance absorption. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H616017815\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall mortality from rhino-orbital-cerebral mucormycosis ranges from 25 to 62 percent, with the best prognosis in patients with infection confined to the sinuses. The prognosis is especially poor for patients with brain, cavernous sinus or carotid involvement, although some patients with these complications have been cured of the infection. The outcome in patients with pulmonary mucormycosis is worse than for patients with rhino-orbital-cerebral involvement, with mortality rates as high as 87 percent. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/1\">",
"      Kauffman CA, Malani AN. Zygomycosis: an emerging fungal infection with new options for management. Curr Infect Dis Rep 2007; 9:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/2\">",
"      Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/3\">",
"      Hibbett DS, Binder M, Bischoff JF, et al. A higher-level phylogenetic classification of the Fungi. Mycol Res 2007; 111:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/4\">",
"      Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 2012; 54 Suppl 1:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/5\">",
"      Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/6\">",
"      GALE GR, WELCH AM. Studies of opportunistic fungi. I. Inhibition of Rhizopus oryzae by human serum. Am J Med Sci 1961; 241:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/7\">",
"      Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am 2000; 33:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/8\">",
"      Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/9\">",
"      Boelaert JR, Van Cutsem J, de Locht M, et al. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994; 45:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/10\">",
"      de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 1994; 47:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/11\">",
"      Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991; 18:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/12\">",
"      Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993; 91:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/13\">",
"      Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/14\">",
"      Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012; 54 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/15\">",
"      Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982; 31:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/16\">",
"      Ibrahim AS, Edwards JE Jr, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006; 58:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/17\">",
"      Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117:2649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/18\">",
"      McNulty JS. Rhinocerebral mucormycosis: predisposing factors. Laryngoscope 1982; 92:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/19\">",
"      Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999; 159:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/20\">",
"      Ismail MH, Hodkinson HJ, Setzen G, et al. Gastric mucormycosis. Trop Gastroenterol 1990; 11:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/21\">",
"      Adam RD, Hunter G, DiTomasso J, Comerci G Jr. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis 1994; 19:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/22\">",
"      Cocanour CS, Miller-Crotchett P, Reed RL 2nd, et al. Mucormycosis in trauma patients. J Trauma 1992; 32:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/23\">",
"      Levy E, Bia MJ. Isolated renal mucormycosis: case report and review. J Am Soc Nephrol 1995; 5:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/24\">",
"      Nagy-Agren SE, Chu P, Smith GJ, et al. Zygomycosis (mucormycosis) and HIV infection: report of three cases and review. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/25\">",
"      Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/26\">",
"      Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/27\">",
"      Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/28\">",
"      Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 2007; 44:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/29\">",
"      Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 Suppl 1:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/30\">",
"      Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/31\">",
"      Lanternier F, Sun HY, Ribaud P, et al. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 2012; 54:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/32\">",
"      Almyroudis NG, Sutton DA, Linden P, et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/33\">",
"      Aslani J, Eizadi M, Kardavani B, et al. Mucormycosis after kidney transplantations: report of seven cases. Scand J Infect Dis 2007; 39:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/34\">",
"      Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/35\">",
"      Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis 2012; 54 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/36\">",
"      Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/37\">",
"      Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/38\">",
"      Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005; 41:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/39\">",
"      Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/40\">",
"      Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006; 44:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/41\">",
"      Rammaert B, Lanternier F, Zahar JR, et al. Healthcare-associated mucormycosis. Clin Infect Dis 2012; 54 Suppl 1:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/42\">",
"      Notes from the field: fatal fungal soft-tissue infections after a tornado --- Joplin, Missouri, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/43\">",
"      Andresen D, Donaldson A, Choo L, et al. Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. Lancet 2005; 365:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/44\">",
"      Pati&ntilde;o JF, Castro D, Valencia A, Morales P. Necrotizing soft tissue lesions after a volcanic cataclysm. World J Surg 1991; 15:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/45\">",
"      Neblett Fanfair R, Benedict K, Bos J, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med 2012; 367:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/46\">",
"      Warkentien T, Rodriguez C, Lloyd B, et al. Invasive mold infections following combat-related injuries. Clin Infect Dis 2012; 55:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/47\">",
"      Harril WC, Stewart MG, Lee AG, Cernoch P. Chronic rhinocerebral mucormycosis. Laryngoscope 1996; 106:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/48\">",
"      Xia ZK, Wang WL, Yang RY. Slowly Progressive Cutaneous, Rhinofacial, and Pulmonary Mucormycosis Caused by Mucor irregularis in an Immunocompetent Woman. Clin Infect Dis 2013; 56:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/49\">",
"      Radner AB, Witt MD, Edwards JE Jr. Acute invasive rhinocerebral zygomycosis in an otherwise healthy patient: case report and review. Clin Infect Dis 1995; 20:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/50\">",
"      Del Valle Zapico A, Rubio Su&aacute;rez A, Mellado Encinas P, et al. Mucormycosis of the sphenoid sinus in an otherwise healthy patient. Case report and literature review. J Laryngol Otol 1996; 110:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/51\">",
"      Elinav H, Zimhony O, Cohen MJ, et al. Rhinocerebral mucormycosis in patients without predisposing medical conditions: a review of the literature. Clin Microbiol Infect 2009; 15:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/52\">",
"      Rajagopalan S. Serious infections in elderly patients with diabetes mellitus. Clin Infect Dis 2005; 40:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/53\">",
"      Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994; 39:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/54\">",
"      Connor BA, Anderson RJ, Smith JW. Mucor mediastinitis. Chest 1979; 75:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/55\">",
"      Helenglass G, Elliott JA, Lucie NP. An unusual presentation of opportunistic mucormycosis. Br Med J (Clin Res Ed) 1981; 282:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/56\">",
"      Tedder M, Spratt JA, Anstadt MP, et al. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/57\">",
"      Brown RB, Johnson JH, Kessinger JM, Sealy WC. Bronchovascular mucormycosis in the diabetic: an urgent surgical problem. Ann Thorac Surg 1992; 53:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/58\">",
"      Murphy RA, Miller WT Jr. Pulmonary mucormycosis. Semin Roentgenol 1996; 31:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/59\">",
"      al-Abbadi MA, Russo K, Wilkinson EJ. Pulmonary mucormycosis diagnosed by bronchoalveolar lavage: a case report and review of the literature. Pediatr Pulmonol 1997; 23:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/60\">",
"      Latif S, Saffarian N, Bellovich K, Provenzano R. Pulmonary mucormycosis in diabetic renal allograft recipients. Am J Kidney Dis 1997; 29:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/61\">",
"      Chavanet P, Lefranc T, Bonnin A, et al. Unusual cause of pharyngeal ulcerations in AIDS. Lancet 1990; 336:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/62\">",
"      Agha FP, Lee HH, Boland CR, Bradley SF. Mucormycoma of the colon: early diagnosis and successful management. AJR Am J Roentgenol 1985; 145:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/63\">",
"      Martinez EJ, Cancio MR, Sinnott JT 4th, et al. Nonfatal gastric mucormycosis in a renal transplant recipient. South Med J 1997; 90:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/64\">",
"      Cheng VC, Chan JF, Ngan AH, et al. Outbreak of intestinal infection due to Rhizopus microsporus. J Clin Microbiol 2009; 47:2834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/65\">",
"      Hosseini M, Lee J. Gastrointestinal mucormycosis mimicking ischemic colitis in a patient with systemic lupus erythematosus. Am J Gastroenterol 1998; 93:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/66\">",
"      Linder N, Keller N, Huri C, et al. Primary cutaneous mucormycosis in a premature infant: case report and review of the literature. Am J Perinatol 1998; 15:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/67\">",
"      Chakrabarti A, Kumar P, Padhye AA, et al. Primary cutaneous zygomycosis due to Saksenaea vasiformis and Apophysomyces elegans. Clin Infect Dis 1997; 24:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/68\">",
"      Wirth F, Perry R, Eskenazi A, et al. Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature. J Am Acad Dermatol 1997; 36:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/69\">",
"      Weinberg WG, Wade BH, Cierny G 3rd, et al. Invasive infection due to Apophysomyces elegans in immunocompetent hosts. Clin Infect Dis 1993; 17:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/70\">",
"      Arn&aacute;iz-Garc&iacute;a ME, Alonso-Pe&ntilde;a D, Gonz&aacute;lez-Vela Mdel C, et al. Cutaneous mucormycosis: report of five cases and review of the literature. J Plast Reconstr Aesthet Surg 2009; 62:e434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/71\">",
"      Weng DE, Wilson WH, Little R, Walsh TJ. Successful medical management of isolated renal zygomycosis: case report and review. Clin Infect Dis 1998; 26:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/72\">",
"      Langston C, Roberts DA, Porter GA, Bennett WM. Renal phycomycosis. J Urol 1973; 109:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/73\">",
"      Melnick JZ, Latimer J, Lee El, Henrich WL. Systemic mucormycosis complicating acute renal failure: case report and review of the literature. Ren Fail 1995; 17:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/74\">",
"      Siddiqi SU, Freedman JD. Isolated central nervous system mucormycosis. South Med J 1994; 87:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/75\">",
"      Hopkins RJ, Rothman M, Fiore A, Goldblum SE. Cerebral mucormycosis associated with intravenous drug use: three case reports and review. Clin Infect Dis 1994; 19:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/76\">",
"      Stave GM, Heimberger T, Kerkering TM. Zygomycosis of the basal ganglia in intravenous drug users. Am J Med 1989; 86:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/77\">",
"      Sanchez MR, Ponge-Wilson I, Moy JA, Rosenthal S. Zygomycosis and HIV infection. J Am Acad Dermatol 1994; 30:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/78\">",
"      Machouart M, Larch&eacute; J, Burton K, et al. Genetic identification of the main opportunistic Mucorales by PCR-restriction fragment length polymorphism. J Clin Microbiol 2006; 44:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/79\">",
"      Hammond SP, Bialek R, Milner DA, et al. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol 2011; 49:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/80\">",
"      Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012; 54 Suppl 1:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/81\">",
"      Saltolu N, Taova Y, Zorludemir S, D&uuml;ndar IH. Rhinocerebral zygomycosis treated with liposomal amphotericin B and surgery. Mycoses 1998; 41:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/82\">",
"      Chamilos G, Marom EM, Lewis RE, et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/83\">",
"      Wahba H, Truong MT, Lei X, et al. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 2008; 46:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/84\">",
"      Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011; 52:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/85\">",
"      Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997; 24:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/86\">",
"      Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/87\">",
"      Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/88\">",
"      Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/89\">",
"      Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/90\">",
"      Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/91\">",
"      Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/92\">",
"      Walsh TJ, Kontoyiannis DP. Editorial commentary: what is the role of combination therapy in management of zygomycosis? Clin Infect Dis 2008; 47:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/93\">",
"      Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008; 198:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/94\">",
"      Spellberg B, Ibrahim A, Roilides E, et al. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis 2012; 54 Suppl 1:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/95\">",
"      Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/96\">",
"      Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/97\">",
"      van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42:e61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/98\">",
"      Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/99\">",
"      Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/100\">",
"      Ferguson BJ, Mitchell TG, Moon R, et al. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 1988; 10:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/101\">",
"      Bentur Y, Shupak A, Ramon Y, et al. Hyperbaric oxygen therapy for cutaneous/soft-tissue zygomycosis complicating diabetes mellitus. Plast Reconstr Surg 1998; 102:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/102\">",
"      Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011; 118:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/103\">",
"      Spellberg B, Andes D, Perez M, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009; 53:3122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/104\">",
"      Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/105\">",
"      Strasser MD, Kennedy RJ, Adam RD. Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Arch Intern Med 1996; 156:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/106\">",
"      Weprin BE, Hall WA, Goodman J, Adams GL. Long-term survival in rhinocerebral mucormycosis. Case report. J Neurosurg 1998; 88:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/46/6890/abstract/107\">",
"      Shah PD, Peters KR, Reuman PD. Recovery from rhinocerebral mucormycosis with carotid artery occlusion: a pediatric case and review of the literature. Pediatr Infect Dis J 1997; 16:68.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2465 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6890=[""].join("\n");
var outline_f6_46_6890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Deferoxamine and iron overload",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H368730430\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368730437\">",
"      Malignancy and hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368730444\">",
"      Solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368730458\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H695986708\">",
"      Healthcare-associated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H695986953\">",
"      Natural disaster-associated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H244297312\">",
"      Combat-associated",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rhino-orbital-cerebral mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gastrointestinal mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cutaneous mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Renal mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Isolated CNS involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Disseminated disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Rhino-orbital-cerebral infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pulmonary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antifungal drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H616017815\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Deferasirox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Rhino-orbital-cerebral infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pulmonary mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2465\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2465|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/43/1713\" title=\"diagnostic image 1\">",
"      Pulmonary mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2465|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/58/5030\" title=\"picture 1\">",
"      Rhizopus hyphae lung tissue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2465|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/34/30254\" title=\"table 1\">",
"      Filamentous fungi MICs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=related_link\">",
"      Fungal rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37849?source=related_link\">",
"      Non-access related infections in chronic dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_46_6891="Pitfalls with plasma proteins";
var content_f6_46_6891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Limitations of the use of plasma proteins to estimate nutritional status in ESRD patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Plasma albumin concentration may be reduced by dilution",
"if the patient is fluid overloaded",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma transferrin may be reduced independent of",
"nutritional status due in part to fluctuations in iron stores",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma prealbumin and retinol-binding protein levels",
"may be increased due to reduced renal catabolism and excretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma levels of nonessential amino acids may be",
"increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Body weight will be elevated by fluid retention",
"independent of muscle mass",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Plasma proteins as estimates of nutritional status. Potential pitfalls in using plasma levels of various proteins to estimate nutritional status in patients with end-stage renal disease.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6891=[""].join("\n");
var outline_f6_46_6891=null;
var title_f6_46_6892="Guidelines after polypectomy I";
var content_f6_46_6892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Surveillance recommendations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Patients with small rectal hyperplastic polyps should be considered to have normal colonoscopies, and therefore the interval before the subsequent colonoscopy should be 10 years; an exception is patients with a hyperplastic polyposis syndrome; they are at increased risk for adenomas and colorectal cancer and need to be identified for more intensive follow-up evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Patients with only 1 or 2 small (&lt;1 cm) tubular adenomas with only low-grade dysplasia should have their next follow-up colonoscopy in 5 to 10 years; the precise timing within this interval should be based on other clinical factors (such as prior colonoscopy findings, family history, and the preferences of the patient and judgment of the physician)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Patients with 3 to 10 adenomas, or any adenoma &ge;1 cm, or any adenoma with villous features, or high-grade dysplasia should have their next follow-up colonoscopy in 3 years providing that piecemeal removal has not been performed and the adenoma(s) are removed completely; if the follow-up colonoscopy is normal or shows only 1 or 2 small tubular adenomas with low-grade dysplasia, then the interval for the subsequent examination should be 5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Patients who have more than 10 adenomas at 1 examination should be examined at a shorter (&lt;3 year) interval, established by clinical judgment, and the clinician should consider the possibility of an underlying familial syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Patients with sessile adenomas that are removed piecemeal should be considered for follow-up evaluation at short intervals (2 to 6 months) to verify complete removal; once complete removal has been established, subsequent surveillance needs to be individualized based on the endoscopist's judgment; completeness of removal should be based on both endoscopic and pathologic assessments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. More intensive surveillance is indicated when the family history may indicate HNPCC",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130:1872. Copyright &copy; 2006 American Gastroenterological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6892=[""].join("\n");
var outline_f6_46_6892=null;
var title_f6_46_6893="Food-borne diseases IV";
var content_f6_46_6893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-IV",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bacterial (cont.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        <em>",
"         Vibrio cholerae",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"5\">",
"        O1 or O139",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"5\">",
"        1-5 days",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"5\">",
"        Watery diarrhea, often accompanied by vomiting",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of toxigenic organism from stool or vomitus of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Significant rise in vibriocidal, bacterial-agglutinating, or antitoxin antibodies in acute- and early convalescent-phase sera among persons not recently immunized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Isolation of toxigenic organism from epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        non-O1 and non-O139",
"       </td>",
"       <td class=\"sublist_other\">",
"        1-5 days",
"       </td>",
"       <td class=\"sublist_other\">",
"        Watery diarrhea",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism of same serotype from stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Vibrio parahaemolyticus",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        4-30 hrs",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea",
"       </td>",
"       <td>",
"        Isolation of Kanagawa-positive organism from stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of &ge;10",
"        <sup>",
"         5",
"        </sup>",
"        Kanagawa-positive organisms/g from epidemiologically implicated food, provided specimen properly handled",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Yersinia enterocolitica",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        1-10 days, usually 4-6 days",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea, abdominal pain (often severe)",
"       </td>",
"       <td>",
"        Isolation of organism from clinical specimen of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of pathogenic strain or organism from epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Chemical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        Marine toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Ciguatoxin",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        1-48 hrs, usually 2-8 hrs",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Usually gastrointestinal symptoms followed by neurologic symptoms (including paresthesia of lips, tongue, throat, or extremities) and reversal of hot and cold sensation",
"       </td>",
"       <td class=\"sublist_other\">",
"        Demonstration of ciguatoxin in epidemiologically implicated fish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Clinical syndrome among persons who have eaten a type of fish previously associated with ciguatera fish poisoning (eg, snapper, grouper, or barracuda)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6893=[""].join("\n");
var outline_f6_46_6893=null;
var title_f6_46_6894="FDG scan I";
var content_f6_46_6894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fluoro-deoxyglucose scan in lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PET scan with FDG shows a right upper lobe solitary pulmonary nodule in cross-sectional (A), sagittal (B), coronal (C) views.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6894=[""].join("\n");
var outline_f6_46_6894=null;
var title_f6_46_6895="Adult shoulder hemiarthroplast";
var content_f6_46_6895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shoulder hemiarthroplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This postoperative anteroposterior radiograph shows a prosthesis that replaces the native humeral head. The shoulder hemiarthroplasty was necessitated by a complex proximal humerus fracture (categorized as \"three-part\" in the Neer system).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_46_6895=[""].join("\n");
var outline_f6_46_6895=null;
